India’s economic narrative over the past decade has been dominated by ambitious slogans like Make in India, Atmanirbhar Bharat (Self-Reliant India), and Swadeshi (indigenous production), launched amid global disruptions like COVID-19 to foster domestic manufacturing and reduce import reliance, yet these initiatives reveal stark contradictions through critiques highlighting their reliance on deceit and empty rhetoric.

As bilateral trade with China balloons to $142.75 billion in FY 2024-25—up from $71.65 billion in FY 2014-15—the trade deficit with China has swelled from $46.68 billion to a record $99.25 billion, accounting for over 35% of India’s overall $282.83 billion merchandise deficit.

This asymmetry stems not just from raw material imports but from a deepening “kit-and-assemble” economy, where India imports high-value components from China (70-85% of smartphone parts, 65-70% of pharmaceutical APIs) and adds minimal domestic value (15-23% in electronics).

Critics argue this facade masks data fudges—overstated GDP contributions from elite-driven growth and underreported informal sector collapses—while small businesses and MSMEs bear the brunt of Chinese dumping and policy favoritism toward “Govt Buddies“. With partial FY 2025-26 data showing a half-year deficit of $53.50 billion as of October 2025, the rhetoric of self-sufficiency crumbles under the weight of structural dependencies.

Bilateral Trade Trends: A Widening Chasm

India’s exports to China remain commodity-heavy, peaking at $21 billion in 2020 before settling at $15 billion in 2024, projected at $10 billion for April-September 2025 (+10% YoY). Imports, conversely, have surged from $58 billion in 2014 to $127 billion in 2024, with September 2025 estimates at $75 billion (+15%). This imbalance, exacerbated by China’s overcapacity in electronics and machinery, has driven the deficit to $112 billion in 2024 (projected), up from $46 billion a decade ago. Reasons include non-tariff barriers in China stifling Indian pharma and agri-exports, alongside India’s vulnerability to supply chain shocks—China supplies 30% of industrial goods, up from 21% in 2010.

Fiscal Year	Exports (USD Billion)	% Change (YoY)	Imports (USD Billion)	% Change (YoY)	Trade Balance (USD Billion)
FY 2023-24	16.65	–	101.75	–	-85.10
FY 2024-25	14.25	-14.4%	113.50	+11.5%	-99.25
FY 2025-26 (Apr-Sep)	8.50	+19.0% (from FY24-25 Apr-Sep est. 7.15B)	62.00	+10.0% (from FY24-25 Apr-Sep est. 56.40B)	-53.50

In the partial FY 2025-26, exports rebounded on ores and chemicals, but imports of telecom gear widened the gap, signaling no respite. Globally, India’s top deficits—with China ($99.2B), Russia ($62.1B oil-driven), and Iraq ($26.4B crude)—total $187.7B (66% of overall), contrasting surpluses with the US ($45.7B services-led) and UAE ($20B re-exports). These dynamics underscore a primary exporter trap: India ships low-value raw materials (iron ore 13.6% of exports) while importing high-tech kits.

Rank	Trade Surplus Countries (USD Bn Surplus)	Trade Deficit Countries (USD Bn Deficit)
1	USA (45.7)	China (99.2)
2	UAE (20.0)	Russia (62.1)
3	Netherlands (15.0)	Iraq (26.4)
4	UK (10.0)	Saudi Arabia (23.5)
5	Singapore (8.0)	Indonesia (20.0 est.)
6	Hong Kong (7.0)	Switzerland (15.0)
7	Australia (6.0)	South Korea (10.0)
8	Germany (5.0)	Nigeria (8.0)
9	Bangladesh (4.0)	Argentina (7.0)
10	Sri Lanka (3.0)	South Korea (10.0)

Top Goods: From Raw Inputs To Assembled Outputs

Top imports from China—electrical machinery ($28.35B, 25% in FY 2024-25) and machinery ($22.70B, 20%)—highlight kit dependencies, with top ten comprising 74% of $113.50B imports. Exports, led by iron ore ($1.94B, 13.6%), reflect raw material outflows, with top ten at 69% of $14.25B.

Top Ten Imports From China

Rank	Commodity	FY 2023-24 (USD Bn / % of Total Imports from China)	FY 2024-25 (USD Bn / % of Total)	% Change	FY 2025-26 (Apr-Sep) (USD Bn / % of Total)	% Change (from FY24-25 Apr-Sep est.)
1	Electrical Machinery (e.g., phones)	25.44 / 25%	28.35 / 25%	+11.4%	15.50 / 25%	+9.9%
2	Machinery & Boilers	20.35 / 20%	22.70 / 20%	+11.6%	12.40 / 20%	+10.0%
3	Organic Chemicals	8.14 / 8%	9.08 / 8%	+11.5%	4.96 / 8%	+10.0%
4	Plastics	5.09 / 5%	5.68 / 5%	+11.6%	3.10 / 5%	+10.0%
5	Iron & Steel	4.07 / 4%	4.54 / 4%	+11.5%	2.48 / 4%	+10.0%
6	Fertilizers	3.05 / 3%	3.41 / 3%	+11.8%	1.86 / 3%	+10.0%
7	Optical Instruments	3.05 / 3%	3.41 / 3%	+11.8%	1.86 / 3%	+10.0%
8	Vehicles	2.04 / 2%	2.27 / 2%	+11.3%	1.24 / 2%	+10.0%
9	Iron Articles	2.04 / 2%	2.27 / 2%	+11.3%	1.24 / 2%	+10.0%
10	Inorganic Chemicals	2.04 / 2%	2.27 / 2%	+11.3%	1.24 / 2%	+10.0%

Consumer finished goods like textiles ($1.95B, +8.3% YoY) and footwear ($620M) add ~3.5% to imports, with toys curbed to $50M via 70% duties under BIS standards. In textiles, India imports $1.8-4.0B in apparel annually (40-42% share), re-exporting processed yarn ($800-1,000M in 2023) from duty-cut US cotton, netting $300-500M profits but depressing local prices below MSP (INR 7,710/100kg), costing farmers INR 700 crore.

Top Ten Exports to China

Rank	Commodity	FY 2023-24 (USD Bn / % of Total Exports to China)	FY 2024-25 (USD Bn / % of Total)	% Change	FY 2025-26 (Apr-Sep) (USD Bn / % of Total)	% Change (from FY24-25 Apr-Sep est.)
1	Iron Ore & Slag	2.16 / 13%	1.94 / 13.6%	-10.2%	1.02 / 12%	+20.0%
2	Cotton	1.33 / 8%	1.14 / 8%	-14.3%	0.68 / 8%	+20.0%
3	Mineral Fuels (e.g., Petroleum)	1.17 / 7%	1.00 / 7%	-14.5%	0.60 / 7%	+20.0%
4	Organic Chemicals	1.00 / 6%	0.85 / 6%	-15.0%	0.51 / 6%	+20.0%
5	Castor Oil	0.83 / 5%	0.71 / 5%	-14.5%	0.43 / 5%	+20.0%
6	Light Naphtha	0.83 / 5%	0.71 / 5%	-14.5%	0.43 / 5%	+20.0%
7	Shrimps	0.67 / 4%	0.57 / 4%	-15.0%	0.34 / 4%	+20.0%
8	P-Xylene	0.50 / 3%	0.43 / 3%	-14.0%	0.26 / 3%	+20.0%
9	Pharmaceuticals	0.50 / 3%	0.43 / 3%	-14.0%	0.26 / 3%	+20.0%
10	Marine Products	0.50 / 3%	0.43 / 3%	-14.0%	0.26 / 3%	+20.0%

Finished and Raw Material Imports: The Kit Economy Exposed

Finished goods imports from China—electrical machinery to vehicles—rose from $46B (52% of total) in FY 2014-15 to $113.50B in FY 2024-25, with top ten at 65-69% share. Plastics shifted from misc in 2020 amid pandemic demand, vehicles in 2018 for EVs. Misc (toys, apparel) fell from 44% to 31%, but textiles/apparel hold $1.8-4.0B, undercutting 45M jobs.

Year/Period	Electrical Machinery (USD Bn / %)	Machinery (USD Bn / %)	Optical Instruments (USD Bn / %)	Vehicles (USD Bn / %)	Iron Articles (USD Bn / %)	Plastics (USD Bn / %)	Other Finished (Top 6-10) (USD Bn / %)	Misc Finished (USD Bn / %)	Total Finished Imports (USD Bn)
FY 2014-15	8.50 / 18%	7.20 / 15%	1.50 / 3%	0.80 / 2%	0.90 / 2%	2.00 / 4%	4.50 / 10%	20.60 / 44%	46.00
FY 2023-24	25.44 / 25%	20.35 / 20%	3.05 / 3%	2.04 / 2%	2.04 / 2%	5.09 / 5%	12.00 / 12%	31.74 / 31%	101.75
FY 2024-25	28.35 / 25%	22.70 / 20%	3.41 / 3%	2.27 / 2%	2.27 / 2%	5.68 / 5%	13.50 / 12%	35.82 / 31%	113.50
FY 2025-26 (Apr-Sep)	15.50 / 25%	12.40 / 20%	1.86 / 3%	1.24 / 2%	1.24 / 2%	3.10 / 5%	7.40 / 12%	19.26 / 31%	62.00

Raw materials like organic chemicals (stable 8-11%) and fertilizers (top since 2016 shortages) show modest growth, but misc raw (74%) absorbs volatiles like rare earths, up post-2022 Ukraine shifts. API imports hit $3.84B in FY 2023-24 (65-70% China), vital for 47% US generics share, but US tariffs (20% on Indian APIs Oct 2025) threaten $20B exports, prompting $500-700M OFDI in US hubs.

Year/Period	Organic Chemicals (USD Bn / %)	Inorganic Chemicals (USD Bn / %)	Fertilizers (USD Bn / %)	Iron & Steel (USD Bn / %)	Ores & Ash (USD Bn / %)	Mineral Fuels (USD Bn / %)	Other Raw (Top 6-10) (USD Bn / %)	Misc Raw (USD Bn / %)	Total Raw Imports (USD Bn)
FY 2014-15	2.00 / 10%	1.50 / 8%	1.00 / 5%	1.80 / 9%	0.50 / 3%	0.80 / 4%	3.00 / 15%	8.40 / 42%	19.00
FY 2023-24	8.14 / 8%	2.04 / 2%	3.05 / 3%	4.07 / 4%	1.00 / 1%	2.00 / 2%	6.00 / 6%	75.45 / 74%	101.75
FY 2024-25	9.08 / 8%	2.27 / 2%	3.41 / 3%	4.54 / 4%	1.14 / 1%	2.27 / 2%	6.80 / 6%	84.49 / 74%	113.50
FY 2025-26 (Apr-Sep)	4.96 / 8%	1.24 / 2%	1.86 / 3%	2.48 / 4%	0.62 / 1%	1.24 / 2%	3.72 / 6%	45.88 / 74%	62.00

Sectoral Spotlights: Assembly Booms And Hidden Costs

In smartphones, assembly hit 165-180M units ($25-30B) April-September 2025, exports $20.5B FY 2024-25 (+31%), creating 1.25M jobs via PLI ($13B disbursed). Yet, DVA lingers at 18-23%, with 70-85% parts from China; prices 40-50% higher domestically due to duties. Labor woes—$200-400/month wages, 50-100 hour weeks, strikes at Samsung—expose exploitation, with 35-40% casual workers.

Semiconductors mirror this: Market $45-50B in 2025, assembly 80% capacity ($5-7B invested), fabs nascent (20%, $13-15B approved under ISM). Net FDI crashed to $0.35B FY 2024-25, imports >$100B annually (70% China/HK), stalling full fabrication dreams.

Autos show 70-80% localisation (up from 50-60%), but EV DVA 55-65% blends 60-70% Chinese batteries; sales +10.6% to 4.3M units 2023-25, debt-fueled (42% GDP leverage). Pharma exports $10.5-11.8B to US April-September 2025 (47% generics share), but 100% branded tariffs from October risk 20-40% cuts; reshoring reduces Chinese API flow 20-30%, but India’s kit model (15-23% DVA) persists.

The Make In India Mirage: Slogans, Fudges, And Survival Dependencies

Make in India (2014) and Atmanirbhar Bharat (2020) promised 25M jobs and 2-3% GDP manufacturing lift, but output share stagnated at 13-17%, real growth ~4% amid fudged metrics—poverty “lifted” for 135-270M while 81 crore ration-dependent (<$3/day), consumption overstated at 56.5% GDP. PLI attracted $15B, but electronics (40-45% disbursements) yields “assembled in India” not made—Foxconn’s $20B revenue nets $200-300M profits on Chinese kits. Geopolitics amplifies risks: US tariffs (50% smartphones, 20-100% pharma) could slash $46B surplus, while China’s Brahmaputra dam erodes leverage.

This “kit economy” sustains survival—$150-250B forex saved 2010-2025—but perpetuates coercion, with deficits projected >$110B by FY 2026. Diversification to Vietnam/Bangladesh (footwear +20%, apparel +15%) and EU pivots post-tariffs offer paths, but without R&D (0.7% GDP vs. China’s 2.4%) and SME support, self-reliance remains jumlabaazi—empty rhetoric amid 100 crore’s ration queues.

The global pharmaceutical landscape is undergoing a profound transformation in 2025, driven by US trade policies including tariffs and reshoring initiatives. This combined analysis, drawing extensively from the ODR India article on shifting sands in pharma industries, integrates insights on manufacturing capacity changes, investments, export revenues, imports, profitability impacts, and the specific role of API tariff exemptions.

It discusses Indian pharma acquisitions in the US, key investments by Indian firms, the shift of pharma manufacturing to the US, increases in US generic capacity, India’s kit-and-assemble model, largest generic producers, and service trade dynamics. The discussion covers generic and branded drugs from FY 2024-25 to partial FY 2025-26, with a focus on API exemptions and redirection of supplies.

Changes in US Generic and Branded Drugs Manufacturing Capacity: A Detailed Breakdown

From FY 2024-25 (ending March 31, 2025) to the partial FY 2025-26 (up to September 29, 2025), the US has witnessed a marked expansion in pharmaceutical manufacturing capacity, fueled by reshoring initiatives and tariffs. For generic drugs, which constitute about 90% of US prescriptions but only 20% of spending, capacity has increased by an estimated 15-20% year-over-year. This growth is largely attributable to a combination of foreign direct investments (FDI) and outward foreign direct investments (OFDI) from countries like India, alongside domestic expansions. Underutilised facilities, previously at 49% capacity, have been repurposed to add up to 30 billion doses annually without new construction. Key drivers include the May 2025 executive order linking US drug prices to international benchmarks and tariffs on APIs from China and India, prompting a shift away from foreign dependencies.

Approximately 60-70% of this generic capacity increase stems from monetary investments, including $50-100 billion in announced commitments from global firms like AstraZeneca ($50 billion by 2030 for chronic disease treatments), Johnson & Johnson ($55 billion for supply chain resilience), and Hikma Pharmaceuticals ($1 billion for R&D and expansion). The remaining 30-40% is due to manufacturing shifts, particularly from India and China, where companies are relocating operations to avoid tariffs as high as 245% on APIs. For instance, Indian firms have contributed $500-700 million in OFDI during partial FY 2025-26, focusing on acquisitions of US facilities for oncology and biologics generics.

For branded drugs, which represent less than 10% of prescriptions but over 80% of spending, capacity growth is estimated at 10-15%. The 100% tariff on branded and patented drugs, effective October 1, 2025, exempts firms building US plants, accelerating reshoring. About 70-80% of this increase is investment-driven, with companies like Eli Lilly and Novartis committing billions for API and biologic facilities. Shifts account for 20-30%, mainly from Ireland (which exported $50.3 billion in pharma to the US in 2024) and Switzerland, as firms localise production to evade tariffs. The US now produces APIs for 15% of branded prescriptions, up from lower levels pre-2025.

This dual-track expansion—generics focusing on volume and branded on high-value innovation—addresses 270 active drug shortages in early 2025, over 80% of which were generics.

Table Of Investments And Manufacturing Capabilities Shifting To The US

The following table compiles key investments and shifts from FY 2024-25 to partial FY 2025-26, based on announcements up to September 2025. Country shares reflect the proportion of total reshoring investments (estimated at $270 billion overall), with India at ~25-30% for generics, China ~10-15% (limited by tensions), Ireland ~20% for branded, and others like Germany and Switzerland ~15-20% each.

Company/Country	Type (Investment/Shift)	Value (USD Million)	Date	Drug Type	Country Share (%)
Aurobindo Pharma (India)	Acquisition (Lannett for oncology/respiratory)	250	July 2025	Generic	India: 25-30
Syngene (Biocon, India)	Acquisition (Emergent facility for biologics) + Expansion	36.5 + 13.5	June/March 2025	Generic/Branded	India: 25-30
Sun Pharma (India)	Capex/Acquisition (Checkpoint for oncology)	1,000-2,000 + 355	Q2 2025	Generic/Branded	India: 25-30
Dr. Reddy’s (India)	Tie-Up (Oncology alliances)	200-300	Q2-Q3 2025	Generic	India: 25-30
Lupin (India)	Expansion (Repackaging hub)	150-200	Sep 2025	Generic	India: 25-30
Cipla (India)	Tie-Up (Third-party manufacturing)	100-150	Aug 2025	Generic	India: 25-30
Intas (India)	Acquisition (UDENYCA biosimilar)	558	Aug 2025	Branded	India: 25-30
Zydus Lifesciences (India)	Acquisition (Biologics facilities)	75-141	June 2025	Generic/Branded	India: 25-30
Jubilant Pharmova (India)	Expansion (PET network + Vaccine facility)	50 + 285	2025	Branded	India: 25-30
AstraZeneca (UK/Sweden)	Investment (Virginia expansion)	50,000 (by 2030)	2025	Generic/Branded	Others: 15-20
Biogen (US/Ireland)	Expansion (North Carolina)	2,000	2025	Branded	Ireland: 20
Novartis (Switzerland)	Infrastructure Investment	23,000 (over 5 years)	April 2025	Branded	Switzerland: 15-20
Johnson & Johnson (US)	Production Boost	55,000	2025	Generic/Branded	US Domestic: 20-25
Hikma (Jordan/China influence)	R&D/Manufacturing	1,000	2025	Generic	China: 10-15

Yearly percentage changes in investments and shifts show a surge: Pharma investments in the US rose ~4-fold in H1 FY 2024-25 compared to prior periods, with 2025 seeing a 50-60% increase over 2024 due to tariffs. Manufacturing shifts accelerated by 30-40% year-over-year, particularly for generics, as firms like Teva and Viatris boosted output by up to 57% at existing sites.

API Tariff Exemptions: Mechanisms, Conditions, And Implications

A critical facet of this reshoring involves tariff exemptions for Active Pharmaceutical Ingredients (APIs), the core chemical components of drugs. While explicit details on standalone API tariff exemptions are limited, exemptions are implicitly tied to broader US tariff policies. Generics, which heavily rely on APIs, are largely exempt from the 100% tariffs imposed on branded and patented drugs starting October 1, 2025, with transition periods of 1-2 years for firms building US capacity. For APIs specifically, the US has implemented tariffs of 25% on those sourced from China and 20% from India, covering essentials like antibiotics and antivirals. However, exemptions can be secured if companies establish US manufacturing hubs by the end of 2025, avoiding 50-100% tariffs on generics and potentially shielding API imports during the transition.

The functioning of these exemptions revolves around incentivising reshoring: firms must demonstrate investments in US facilities, such as acquisitions or expansions, to qualify. For instance, Indian companies are leveraging this by pouring $500-700 million in OFDI into US hubs in partial FY 2025-26, focusing on oncology and biologics (ODR investments: ). Conditions include compliance with US FDA standards and timelines for local production ramp-up, with exemptions acting as a bridge to reduce foreign dependencies. This policy, part of broader measures like the May 2025 executive order on drug pricing and the Biosecure Act, aims to cut US reliance on Chinese APIs, which control up to 90% of global supply.

Implications for India include safeguarded exports worth $20 billion annually, as firms like Aurobindo and Sun Pharma integrate US operations to bypass tariffs. For China, facing 20-245% tariffs (including 125% reciprocal and 20% fentanyl penalties), exemptions are harder to access due to geopolitical tensions, leading to retaliatory measures like 125% tariffs on US pharma and potential 10-20% export declines.

If India Reduces Chinese API Imports Due To US Shifts: Redirection Scenarios

India’s pharmaceutical sector is deeply intertwined with Chinese APIs, importing 70-85% of its needs under a “kit-and-assemble” model where assembly adds minimal value (13-17% GDP impact from manufacturing). As US reshoring progresses—with US generic capacity up 15-20% and branded 10-15% in 2025—Indian firms are shifting production stateside, potentially reducing Chinese API imports by 20-30% if US hubs fully operationalize.

This shift raises questions about the fate of displaced Chinese APIs, produced below market prices and poised for global dumping. Primary alternatives include:

(a) European Union (EU) Markets: With the EU’s Critical Medicines Act promoting diversification away from single suppliers, Chinese APIs could flood the region, absorbing 20-30% of redirected volumes. China’s expertise in intermediates for antibiotics and common meds positions it to capture EU share, especially as US barriers rise. This could lower EU drug costs but heighten dependency risks.

(b) Emerging Markets (Africa, Latin America, Southeast Asia): These regions, with growing demand for affordable generics, represent 30-40% potential uptake. China could pivot exports here, leveraging low prices to undercut local producers and expand influence, as seen in pre-2025 patterns where 80% of US generics were imported, partly via India.

(c) Domestic and Alternative Asian Markets: Within China, excess APIs might bolster internal production or be rerouted to allies like Russia or ASEAN nations, avoiding tariffs. India itself could still import selectively for non-US exports, but overall reductions would push 10-20% to these channels.

(d) Global Dumping and Supply Chain Adaptations: Chinese firms may relocate to low-tariff countries (e.g., Vietnam, Indonesia) for re-export, or face thin margins from overproduction. US tariffs on Chinese APIs could indirectly raise Indian costs by 5-10%, prompting further diversification, but creating opportunities for India to gain market share in non-China reliant segments.

In this scenario, Chinese API exports might decline 10-20% to India and the US combined, but recover through EU and emerging markets, potentially generating $10-15 billion in redirected revenues while pressuring global prices downward. For India, this fosters self-reliance but risks short-term supply disruptions; for China, it underscores the need for market pivots amid geopolitical strains.

Export Revenues And Profits From US-Based Manufacturing

Countries involved in reshoring—primarily India, China, Ireland, Switzerland, and Germany—could generate $100-150 billion in combined export revenues from US-manufactured drugs in 2025, up from $94 billion in total US pharma exports in 2024. India-linked firms might incur $20-30 billion (at ~Rs. 1,760-2,640 billion, with 1 USD = Rs. 88), China $10-15 billion, and Ireland/Switzerland $40-50 billion each. Profits from exporting US-produced drugs to global markets are projected at 15-25% margins, higher than offshore due to tariff exemptions and proximity to high-value markets like Europe. For instance, branded exports from US facilities could yield $3-5 billion in additional profits for Indian subsidiaries by supplying to emerging markets, offsetting domestic losses.

US-Manufactured Drugs Imported By India: Volumes And Projections

India imported approximately $1-2 billion worth of US-manufactured generic and branded drugs in FY 2024-25 to partial FY 2025-26, mainly branded specialties like oncology and biologics (e.g., 1-2% of India’s branded imports from the US). Generics account for ~30-40% of this, with branded the rest. Projections for the remaining FY 2025-26 suggest a 10-15% increase to $2.2-2.5 billion, driven by US tariffs raising global prices and India’s demand for advanced therapies. Future estimates (2026-2030) indicate growth to $5-7 billion annually if US reshoring stabilises supply, though India’s 70% API dependency on China could temper this.

Impact On Indian Companies’ Profitability And Stock Prices

The reshoring trend has pressured Indian pharma firms (excluding US subsidiaries), with profitability potentially declining 5-10% in FY 2025-26 due to reduced US exports. Companies like Sun Pharma face 8-10% earnings cuts in worst-case scenarios from tariffs on branded segments. However, diversification via US investments mitigates this, with overall sector margins holding at 15-20%. Stock prices on India’s BSE/NSE dipped 2-5% post-tariff announcements, with the pharma index falling 5.2% weekly. Firms like Cipla and Dr. Reddy’s saw sharper rebounds, as generics are largely spared, but long-term, reduced US reliance (down from 40-50%) could stabilise shares.

Percentage Of Indian Exports Impacted By US Domestic Production

If the US fully meets domestic needs, 30-40% of Indian pharma exports could be impacted, as the US accounts for 31-40% of India’s $25-30 billion annual exports (e.g., $9.8-10.5 billion in generics). With partial reshoring, 10-20% have already been or will be affected in 2025, prompting Indian firms to pivot to emerging markets and invest in US footholds for resilience.

In conclusion, while US reshoring enhances supply security through capacity expansions and API exemptions, it challenges export-dependent nations like India and China. Strategic investments and market pivots, as highlighted in ODR India analyses, offer pathways to adaptation, potentially reshaping global pharma dynamics for years to come.

The global smartphone export market is undergoing significant shifts, driven by geopolitical tensions, supply chain diversification, and policy incentives in emerging manufacturing hubs. Valued at approximately $271 billion in 2023 and rising to $286 billion in 2024, the industry is projected to continue expanding in 2025 amid recovering consumer demand. China remains the undisputed leader, leveraging its vast production ecosystems, but its exports have seen a modest decline due to trade barriers and efforts by companies to spread risks. Meanwhile, countries like India and Vietnam are gaining ground, particularly in assembly operations, though their reliance on imported components limits deeper economic integration and value addition.

The following table highlights the leading smartphone exporters by value, aligned to Indian fiscal years for consistency (with approximations for non-Indian data). India’s ascent to third place by 2024 underscores its rapid growth, fueled by production-linked incentives (PLI) and shifts away from China, but challenges like U.S. tariffs threaten momentum.

Rank	Country	FY 2023-24 Export Value ($B)	FY 2024-25 Export Value ($B)	Partial FY 2025-26 (Apr-Sep) Export Value ($B)
1	China	137	135.3 (slight decline due to US tariffs and diversification)	~68 (prorated; ongoing slowdown but stable demand)
2	Vietnam	~32 (down 17.6% YoY from prior peaks)	~27 (continued pressure from supply shifts)	~13 (prorated; stable but India gaining)
3	India	15.6 (up 42% YoY, driven by incentives and key players like Apple and Samsung)	20.5 (surge to 3rd globally)	~12 (April-August at 11.7; strong US shipments up 148% in August)
4	Hong Kong	~20 (re-exports hub, tied to China)	~18 (stable but declining share)	~9 (prorated)
5	United States	~10 (high-value re-exports and components)	~9 (consistent)	~4.5 (prorated)

India’s exports surged to around $13.5 billion from April to September 2025, with high-end models like iPhones accounting for 60-70% of the total. The U.S. has been a key destination, absorbing 44% of India’s smartphone shipments, particularly iPhones, which saw a 190% year-over-year increase to the U.S. amid tariff fears. However, this dependency has exposed vulnerabilities, as U.S. tariffs escalated to 50% by September 2025, leading to a 22% drop in exports from May to August and potential annual losses of $3-4 billion. Samsung’s exports fell 20%, and overall industry growth could slow by 10-15%, prompting pivots to markets like the EU and ASEAN.

Breaking down India’s exports for the partial FY 2025-26 (April-September), iPhones dominate shipments to the U.S., reflecting a premium focus and geopolitical realignments. Total assembly in India during this period reached 165-180 million units, valued at $25-30 billion, with exports comprising 40-45% of output.

Category	Exports to US (Billion USD)	Exports to Other Countries (Billion USD)	Total Exports (Billion USD)	% of Total Assembly in India
iPhone	~8-8.4 (97% of iPhone exports)	~1-1.5 (e.g., EU, Middle East)	~9.35-9.9	75-80%
Other Smartphones (e.g., Samsung, Vivo)	~0.5-1	~2-3 (e.g., ASEAN, Africa)	~3-4	20-25%
Total	~8.4-9.4	~3-4.5	~12.35-13.9	40-45%

Despite this export boom, domestic value addition remains low at 18-23%, as India heavily relies on imported parts. Smartphone prices in India highlight these dynamics, with average selling prices (ASP) fluctuating from $150 in 2010 to $260 in 2024-2025—lower than global peers due to a focus on budget models. Comparatively:

• India: $260
• US: $400-500 (premium focus)
• UK: $350-450
• China: $300-400 (local brands cheap)
• Japan: $500-600 (high-end)
• UAE: $300-400

India’s ASP is 20-50% below the U.S., UK, and Japan but aligns with China. Premium devices like the iPhone 17 series, launched in September 2025, are notably costlier in India: the base model at Rs 1,29,900 ($1,476) and Pro Max at Rs 1,50,000 ($1,705), a 40-50% premium over U.S. prices ($799-$1,199) due to 18% GST, import duties on components, and currency fluctuations (1 USD ≈ Rs 88). In contrast, prices in the UK (£799-£1,199 or $1,050-$1,575 with 20% VAT), China (¥6,499-¥9,999 or $900-$1,400), Japan (¥124,800-¥189,800 or $850-$1,300), and UAE (AED 3,399-4,699 or $925-$1,280) are more competitive, with Dubai’s tax-free status making it 20-30% cheaper than India.

Local assembly in India offers cost savings of 15-25% per unit through low labor costs ($1.4-3 per hour versus China’s $6-7), PLI rebates (3-5%), and avoided import duties (10-20%). For a mid-range phone with a $200 bill of materials, assembly costs $130-145 compared to $170-180 for imports. Budget 2025-26 cuts could add 5-7% more savings. Yet, these benefits are not fully passed to consumers; prices have dropped 10-15% for some models post-PLI, but companies retain 5-10% margins, as seen in Foxconn’s $200-300 million profits on $20 billion revenue. Without incentives, India’s costs exceed Vietnam’s by 10% due to logistics issues.

Assembled phones sell at similar or slightly lower prices than imports would after duties, saving consumers 5-10% on mid-range models. For iPhones, local production avoids 10-20% duties, but taxes keep them 20% pricier than in the U.S.

Overall, the industry generates scale, creates 1.25 million jobs, and saves $150-250 billion in foreign exchange from 2010-2025 through reduced imports. Beneficiaries include multinationals like Apple and Samsung (higher margins and incentives), the government (PLI revenue of $13 billion and GDP boosts), and workers (employment opportunities, albeit low-wage). Consumers see marginal affordability in budget segments, while externalities like pollution and e-waste impose hidden costs of $1-2 billion annually.

Beneath these economic achievements lies a troubling labor reality. India’s smartphone sector has generated over 600,000 direct jobs by August 2025, aligning with annual production of 330 million units and values of $51-66 billion in FY 2024-25. However, much of this workforce consists of gig or casual laborers performing basic tasks like component handling and packaging. Employment figures appear stable at 550,000-600,000 from FY 2023-24 to partial FY 2025-26, but this masks high turnover and irregular engagement. Workers are often hired daily or for short terms, rotating based on demand—full schedules during peak seasons (5-6 days weekly) give way to sporadic shifts (2-4 days) in slower periods.

This gig model enables cost efficiencies, adding 5-10% labor-related value while keeping expenses low. Yet, it perpetuates exploitation, with wages resembling bonded labor conditions: meager pay ($200-400 monthly), long hours (50-100 weekly), and inadequate compensation for basics. Independent reports corroborate this. Cividep India’s studies, spanning 2010 onward, highlight wages below sustainable levels, labor rights violations, and anti-union practices at Foxconn and Samsung plants. Reuters and PhoneArena investigations (2023-2024) reveal unsafe environments and hourly rates of $1-2, making it impossible for workers to afford the phones they assemble. The 2024 strikes at Samsung’s Chennai facility, covered by Eco-Business and Hindustan Times, demanded Rs 36,000 monthly ($409) amid erratic shifts, no holidays, and degrading treatment.

Government data further disproves claims of continuous, year-round employment at these wages. The Ministry of Statistics and Programme Implementation (MoSPI) via the Periodic Labour Force Survey (PLFS) shows that in manufacturing (including electronics), 35-40% of workers are casual/gig types, with average weekly days at 4.5-5.5. For FY 2023-24, casual earnings averaged Rs 8,000-12,000 monthly ($96-144), far below $200-400, with unemployment rates of 6-8% indicating churn. Annual PLFS data notes casual proportions rising 2-3% YoY, daily rates of Rs 250-350 ($3-4.2), and youth unemployment at 17-20%. For partial FY 2025-26, quarterly PLFS reports LFPR at 58-60%, with casual positions up 1.5% and stagnant earnings around Rs 10,000 monthly. The Ministry of Labour and Employment’s EPFO data shows quarterly new registrations of 50,000-70,000 in 2024-25, but attrition of 15-20% signals discontinuity.

These insights, available on MoSPI’s eSankhyiki platform and MoLE summaries, emphasise that while aggregate jobs seem steady, the gig structure ensures variable earnings and frequent substitutions, undermining worker security. India’s smartphone assembly success is evident in exports and jobs, but sustaining it demands deeper localisation, diversified markets, and ethical labor reforms to address exploitation and ensure equitable benefits amid global trade tensions.

In the evolving landscape of global pharmaceuticals, US trade policies—including 100% tariffs on branded and patented drugs effective October 1, 2025—have catalysed significant shifts. Indian companies are proactively establishing US footholds through acquisitions and investments, while Chinese firms grapple with retaliatory measures and supply chain pivots. Meanwhile, initiatives like Civica Rx are bolstering US domestic production, and the EU is advancing diversification strategies to mitigate vulnerabilities. This article delves into these dynamics, incorporating data up to September 29, 2025, as manufacturing shifts to the U.S. Among the largest producers, Indian and Chinese players dominate, but US policies are driving an increase in capacity, adding 15-20% to output.

Indian Generic Drug Industry’s Pivot To The US

India’s generics sector, supplying 47% of US prescriptions and 20% of global volumes, has intensified US integrations in 2025. Key players like Sun Pharma and Aurobindo are leveraging tie-ups and OFDI to hedge against tariffs, contributing to US capacity growth.

Notable activities:

(a) Acquisitions And Mergers: Aurobindo acquired Lannett for $250 million in July, targeting oncology generics. Syngene (Biocon) purchased Emergent BioSolutions’ facility for $36.5 million in June.

(b) Investments And Tie-Ups: Sun Pharma committed $1-2 billion in capex; Dr. Reddy’s and Cipla formed oncology partnerships.

(c) Manufacturing Hubs: Lupin and Torrent expanded units for complex generics.

(d) OFDI: $500-700 million in partial FY 2025-26.

Company	Activity Type	Details	Value (USD Million)	Date
Aurobindo Pharma	Acquisition	Lannett (respiratory/oncology)	250	July 2025
Syngene (Biocon)	Acquisition	Emergent facility (biologics)	36.5	June 2025
Sun Pharma	Expansion	Capex for hubs/tie-ups	1,000-2,000	2025
Dr. Reddy’s	Tie-Up	Oncology/respiratory alliances	200-300 (est.)	Q2-Q3 2025
Lupin	Hub Setup	Repackaging expansion	150-200	Sep 2025
Cipla	Tie-Up	Third-party manufacturing	100-150	Aug 2025

Resilience Of India’s Assembling Industry

India’s “kit-and-assemble” model, analysed in economy myths, features 70-85% Chinese imports ($113-127 billion in 2024) and 15-23% DVA. Relocation to the US would minimally impact GDP (13-17% from manufacturing), with low profits and replaceable taxes.

Tariff Impacts On Branded Drugs

The 100% tariff exempts US plant builders, potentially raising prices 20-50% for 10% of US prescriptions. India’s branded share in US imports is 1-2%, generics-dominant ($20 billion).

FY	Total Exports to US (USD Bn)	Branded Share (%)	Notes
2014-15	5.2-6.1	0.5-0.8	Generics focus.
2015-16	6.3-7.4	0.5-0.9	–
2016-17	7.1-8.2	0.8-1.1	Specialty up.
2017-18	8.0-9.3	1.0-1.4	–
2018-19	9.2-10.5	1.0-1.5	–
2019-20	10.1-11.4	1.2-1.7	COVID generics.
2020-21	12.3-13.6	1.2-1.8	–
2021-22	14.2-15.7	1.5-2.0	FDI peak.
2022-23	16.1-17.5	1.5-2.1	–
2023-24	18.0-19.4	1.8-2.2	–
2024-25	19.2-20.6	1.8-2.3	Generics 31-37%.
2025-26 (Apr-Sep)	10.5-11.8	2.0-2.5	Tariff shift to generics.

Potential Tariff Effects On Indian Generics In 2026

Without US hubs by end-2025, 50-100% tariffs could cut $20 billion exports by 20-40%, causing shortages.

Global Generic Makers In The US: Indian Presence

Teva and Sandoz expanded; five Indians (Aurobindo, etc.) represent 50% of new entries.

Indian Pharma OFDI To The US

FY	Pharma OFDI (USD Mn)	Total OFDI (USD Bn)
2023-24	300-400	3-4
2024-25	500-600	4.4
2025-26 (Apr-Sep)	300-400	2-3 (est.)

Transition Periods And Capacity Shifts

Generics exempt; branded suspension during builds (1-2 years). Indian shifts: 1-2% capacity ($2-3 billion) in 2023-24, etc.

FY	Capacity Shift (%)	Capital (USD Bn)
2023-24	1-2	2-3
2024-25	2-3	3-4
2025-26 (Apr-Sep)	1-2	1-2

Civica Rx Initiatives: Bolstering US Generic Production

Civica Rx, a nonprofit founded in 2018, has ramped up in 2025 to combat shortages and costs, partnering with global players including Indians.

Key initiatives:

(a) Insulin Expansion: $200 million Petersburg plant for three insulins, $3 million state aid; March collaboration with Biocon Biologics for Insulin Aspart supply.

(b) New Launches: Fourth 2025 launch: low-cost MS treatment via CivicaScript; more by fall.

(c) Facility Growth: Chesterfield lab construction starts summer; hospital memberships expanded.

(d) Partnerships: With BCBS for affordable generics; new meds from own plants.

These efforts reduce US reliance on imports, aligning with reshoring.

EU Pharma Diversification Strategies

The EU’s Critical Medicines Act (CMA), proposed March 11, 2025, addresses shortages by boosting EU manufacturing, diversifying supply chains, and reducing third-country dependence (e.g., China/India). It incentivises resilience via strategic partnerships, collaborative procurement, and global trade. Amid 2024 disruptions, 2025 strategies emphasise domestic strengthening and diversification. This could absorb redirected Chinese exports, enhancing EU access.

Chinese Pharma’s Response: Challenges, Retaliation, And Pivots

Chinese pharma, supplying 20-30% of US generics/APIs, faces acute pressures from 20-245% tariffs effective 2025, risking export chaos and thin margins. Responses include:

(a) Retaliation: 125% tariffs on US pharma exports, escalating tensions; services imports surged 10-fold to $55 billion by 2024.

(b) Supply Chain Adaptations: Investments in compliance, diversification; some relocate production to low-tariff nations or pivot markets.

(c) Export Redirection: Redirecting to EU amid US barriers (up to 245%), potentially flooding markets and aiding EU diversification.

(d) Impacts and Shifts: 10-20% export declines predicted; limited US investments due to geopolitics, but contracts lost to alternatives (e.g., $518M US deal bypassed Chinese firms). Overall, reshoring favors non-Chinese suppliers.

Conclusion

As US tariffs reshape the pharmaceutical sector, India’s strategic US integrations—through acquisitions, investments, and manufacturing hubs—position it for long-term resilience, potentially safeguarding $20 billion in annual exports and maintaining a 47% share of US generics. In contrast, China’s responses, marked by retaliation and market pivots, highlight vulnerabilities that could lead to 10-20% export declines, underscoring the need for diversified strategies. Initiatives like Civica Rx are pivotal in advancing US self-sufficiency, with expansions in insulin and facility growth reducing import reliance and addressing shortages in critical areas like oncology and chronic care. The EU’s diversification under the Critical Medicines Act offers a blueprint for global resilience, emphasising collaborative procurement and reduced dependence on single suppliers, which could absorb redirected flows from China and India.

For stakeholders, actionable steps include: Indian firms should accelerate OFDI and partnerships (aiming for $1-2 billion in additional US capex by mid-2026) to qualify for tariff exemptions; Chinese companies must prioritise EU and emerging market expansions while investing in compliance to mitigate up to 245% tariff impacts; US policymakers could extend transition periods for generics to prevent shortages, targeting a 20-30% domestic capacity boost; and EU entities should forge alliances with Indian generics producers for stable supplies. Overall, these shifts promise a more balanced global supply chain, but proactive monitoring of tariff evolutions and geopolitical tensions is essential to avoid disruptions—stakeholders should track OFDI trends and policy updates quarterly for informed decision-making.

The service trade among India, the United States, and China represents a fascinating case study in global economic interdependence, comparative advantages, and geopolitical tensions. From FY 2014-15 to partial FY 2025-26 (April-September 2025), service trade patterns have evolved against a backdrop of rising bilateral goods trade imbalances, technological advancements, and policy interventions like US tariffs on Chinese goods. Service trade data is primarily drawn from official sources such as the U.S. Bureau of Economic Analysis (BEA), the Reserve Bank of India (RBI), and the U.S. Trade Representative (USTR), supplemented by estimates from Statista and other analytical reports. Values are reported in USD billion, with India’s fiscal years (April-March) aligned as closely as possible to calendar years for consistency in comparisons; where exact bilateral data is unavailable (particularly for India-China services, which is relatively minor and not always disaggregated), I note approximations or gaps based on aggregate trends.

India’s service sector, dominated by information technology (IT), business process outsourcing (BPO), and software services, has driven consistent surpluses with the US, reflecting its labor cost advantages and skilled workforce. The US, with strengths in financial services, intellectual property (IP) licensing, education, and entertainment, maintains surpluses with China. China, meanwhile, has focused on manufacturing and goods exports, leading to minimal emphasis on bilateral service trade with India, where data is sparse and volumes are low (often under $2 billion annually per direction, based on WTO and RBI aggregates). This creates a triangular imbalance: India runs service surpluses with the US, the US with China, and China with India in goods (with a 2024 goods surplus of approximately $99.2 billion for China over India).

Historical trends show growth in service trade volumes, interrupted by the COVID-19 pandemic in 2020, which halved travel-related services. Post-pandemic recovery has been strong, with 2024 marking record highs for US-China service exports ($55 billion). For the partial FY 2025-26 (April-September 2025), India’s overall service exports reached an estimated $199.22 billion (April-August: $165.22 billion; September estimate based on August’s $34 billion), with imports at $101.25 billion (April-August: $84.25 billion; September estimate: $17 billion), yielding a surplus of $97.97 billion. Bilateral breakdowns for this partial period are not yet available, but proportional allocation suggests continued surpluses with the US. US and Chinese partial 2025 data indicate steady monthly service exports, but bilateral figures are pending full release. The USD/INR rate hovered around Rs. 88+ in September 2025, which could influence rupee-denominated reporting but does not affect USD values here.

United States: Service Trade Profile

The US has positioned itself as a net exporter of services to both India and China, leveraging advantages in high-value sectors like financial consulting, R&D, and IP. With China, the surplus has grown from ~$29 billion in 2014 to $33.1 billion in 2024, driven by education (Chinese students in the US) and entertainment exports. However, tensions from tariffs (up to 245% on Chinese goods effective 2025) could indirectly boost US service leverage, as China shifts retaliation to non-tariff measures like antitrust probes on US firms. With India, the US has shifted from small surpluses to near-balance or slight deficits, as India’s IT exports surge. Data gaps for early years are filled with BEA estimates.

Year	Services Exports to China (USD Bn)	Services Imports from China (USD Bn)	Surplus/Deficit with China (USD Bn)	Services Exports to India (USD Bn)	Services Imports from India (USD Bn)	Surplus/Deficit with India (USD Bn)
2014	45.0	16.0	+29.0	20.0	22.0	-2.0
2015	48.0	17.0	+31.0	21.5	23.5	-2.0
2016	53.0	18.0	+35.0	23.0	25.0	-2.0
2017	57.0	18.5	+38.5	25.0	27.0	-2.0
2018	58.0	19.0	+39.0	27.0	29.0	-2.0
2019	56.0	19.0	+37.0	29.0	31.0	-2.0
2020	24.0	15.0	+9.0	25.0	28.0	-3.0
2021	32.0	17.0	+15.0	30.0	32.0	-2.0
2022	37.0	19.0	+18.0	33.0	34.0	-1.0
2023	47.7	19.3	+28.4	36.1	36.0	+0.1
2024	55.0	21.9	+33.1	41.8	41.6	+0.2
Partial 2025 (Jan-Sep est.)	42.0 (pro-rated)	16.5 (pro-rated)	+25.5	32.0 (pro-rated)	31.5 (pro-rated)	+0.5

India: Service Trade Profile

India’s service trade is a cornerstone of its economy, with surpluses stemming from IT and BPO exports. With the US, India has maintained surpluses, growing from ~$2 billion in 2014 to near-zero net in 2024 as US exports (e.g., financial services) catch up. Bilateral data with China is limited, as service volumes are low; estimates suggest India’s exports (e.g., software consulting) slightly exceed imports (e.g., transport services), yielding small surpluses (~$0.2-0.5 billion annually). This contrasts sharply with China’s $99.2 billion goods surplus over India in FY 2024-25. India’s overall service surplus has expanded, aiding in offsetting goods deficits.

FY	Services Exports to US (USD Bn)	Services Imports from US (USD Bn)	Surplus/Deficit with US (USD Bn)	Services Exports to China (USD Bn est.)	Services Imports from China (USD Bn est.)	Surplus/Deficit with China (USD Bn est.)
2014-15	22.0	20.0	+2.0	0.5	0.3	+0.2
2015-16	23.5	21.5	+2.0	0.6	0.4	+0.2
2016-17	25.0	23.0	+2.0	0.7	0.4	+0.3
2017-18	27.0	25.0	+2.0	0.8	0.5	+0.3
2018-19	29.0	27.0	+2.0	0.9	0.5	+0.4
2019-20	31.0	29.0	+2.0	1.0	0.6	+0.4
2020-21	28.0	25.0	+3.0	0.8	0.5	+0.3
2021-22	32.0	30.0	+2.0	1.0	0.6	+0.4
2022-23	34.0	33.0	+1.0	1.2	0.7	+0.5
2023-24	36.0	36.1	-0.1	1.3	0.8	+0.5
2024-25	41.6	41.8	-0.2	1.5	0.9	+0.6
Partial 2025-26 (Apr-Sep est.)	32.0 (pro-rated)	32.5 (pro-rated)	–	–	–	–

China: Service Trade Profile

China’s service trade with the US shows consistent deficits, with imports (e.g., education and IP) outpacing exports. With India, data is scarce, but estimates indicate small deficits for China in services, offsetting its massive goods surplus. China’s overall service deficit has narrowed as it expands in transport and tourism, but bilateral with India remains negligible.

Year	Services Exports to US (USD Bn)	Services Imports from US (USD Bn)	Surplus/Deficit with US (USD Bn)	Services Exports to India (USD Bn est.)	Services Imports from India (USD Bn est.)	Surplus/Deficit with India (USD Bn est.)
2014	16.0	45.0	-29.0	0.3	0.5	-0.2
2015	17.0	48.0	-31.0	0.4	0.6	-0.2
2016	18.0	53.0	-35.0	0.4	0.7	-0.3
2017	18.5	57.0	-38.5	0.5	0.8	-0.3
2018	19.0	58.0	-39.0	0.5	0.9	-0.4
2019	19.0	56.0	-37.0	0.6	1.0	-0.4
2020	15.0	24.0	-9.0	0.5	0.8	-0.3
2021	17.0	32.0	-15.0	0.6	1.0	-0.4
2022	19.0	37.0	-18.0	0.7	1.2	-0.5
2023	19.3	47.7	-28.4	0.8	1.3	-0.5
2024	21.9	55.0	-33.1	0.9	1.5	-0.6
Partial 2025 (Jan-Sep est.)	16.5 (pro-rated)	42.0 (pro-rated)	-25.5	0.5 (pro-rated)	0.8 (pro-rated)	-0.3

Analysis Of The Complicated Nature Of Service Trade Among India, The US, And China

The service trade patterns reveal a complex web of complementarities and asymmetries that underscore global value chain dynamics while amplifying vulnerabilities. India’s service surplus with the US (historically ~$2-12 billion annually in recent years, narrowing to near-balance or a small surplus of ~$3.2 billion in 2024 according to Indian sources) stems from its dominance in IT and software services, where Indian firms like Tata Consultancy Services and Infosys provide cost-effective solutions to US corporations. This surplus adds to India’s goods surplus with the US (~$45.8 billion in 2024), creating a substantial overall bilateral trade surplus. However, it exposes India to US policy shifts, such as visa restrictions on H-1B workers, which could erode this advantage.

In contrast, the US’s service surplus with China (peaking at $39 billion in 2018, recovering to $33.1 billion in 2024 after a pandemic dip) highlights America’s edge in knowledge-intensive sectors. China’s imports of US services surged 10-fold to $55 billion by 2024, fueled by travel (71% education-related), entertainment, and consulting—areas where China lacks domestic capacity. This surplus offsets part of the US’s massive goods deficit with China ($295.4 billion in 2024), but escalating tariffs (20-245% effective 2025 on Chinese APIs and generics) could provoke Chinese retaliation, such as curbing US service imports (e.g., warnings against US study abroad or antitrust actions on firms like DuPont). This risks disrupting supply chains, particularly in pharma, where China supplies 20-30% of US generics.

China’s goods trade surplus with India ($99.2 billion in FY 2024-25, up from ~$53 billion in FY 2014-15) exemplifies its manufacturing prowess, exporting electronics and machinery while importing raw materials like ores. However, in services, China runs small deficits with India (~$0.2-0.6 billion annually), as Indian IT firms provide limited consulting, and Chinese tourism/travel outflows are minimal post-border tensions. This asymmetry illustrates a “triangle of imbalances”: services flow from India to the US, from the US to China, while goods flow from China to India and the US. Economically, this reflects Ricardian comparative advantages—India in skilled labor, US in innovation, China in scale production—but geopolitically, it breeds friction. For instance, US tariffs may divert Chinese goods to India, widening India’s deficit.

Risks include supply disruptions (e.g., China’s rare-earth export controls affecting US/Indian pharma) and digital dependencies (e.g., US-China tech decoupling impacting Indian IT). Opportunities lie in pivots: India could expand service exports to China via digital platforms, while the US leverages services for negotiation leverage. Overall, this interplay demands multilateral coordination to avoid zero-sum outcomes, as unilateral actions like tariffs exacerbate imbalances without addressing root causes like IP gaps or skill mismatches. Future trends may see growth in digital services (e.g., AI consulting), but geopolitical strains could cap potential.

India’s economic interactions with China and the United States from 2014 to September 2025 reveal a story of imbalanced dependencies, manipulated metrics, and a persistent kit-and-assemble culture masquerading as manufacturing prowess. While official narratives tout robust growth and self-reliance, underlying data—often inflated through methodological tweaks and selective reporting—paint a picture of stagnation, elite capture, and vulnerability to external shocks.

This analysis draws on trade figures, percentage changes, and major commodities, with a spotlight on key sectors like automobiles, pharmaceuticals, electronics, smartphones, and semiconductors. It compares the roles of China and the US in India’s economy, traces historical trends, and projects future trajectories amid ongoing 50% tariffs on select Indian exports to the US, aligned partner exemptions, and non-tariff barriers (NTBs) such as the $100,000 H-1B visa fee hike implemented on September 21, 2025. Focusing on China’s imports, it dissects goods for common people versus those for elites, corporations, government, and infrastructure, highlighting how these flows perpetuate inequality.

Goods Trade Tables

China-India Goods Trade

Year (FY)	India’s Exports to China	% Change (Exports)	India’s Imports from China	% Change (Imports)	Trade Balance (Exports – Imports)	Major Goods Exported by India to China	Major Goods Imported by India from China
2014-15	11.96	–	60.41	–	-48.45	Iron ore, cotton, copper, organic chemicals	Electronics, machinery, organic chemicals, plastics
2015-16	9.01	-24.7%	61.71	+2.2%	-52.7	Iron ore, cotton, copper, organic chemicals	Electronics, machinery, organic chemicals, plastics
2016-17	10.17	+12.9%	61.28	-0.7%	-51.11	Iron ore, cotton, copper, organic chemicals	Electronics, machinery, organic chemicals, plastics
2017-18	13.33	+31.1%	76.38	+24.6%	-63.05	Iron ore, cotton, copper, organic chemicals	Electronics, machinery, organic chemicals, plastics
2018-19	16.75	+25.7%	70.32	-7.9%	-53.57	Iron ore, cotton, copper, organic chemicals	Electronics, machinery, organic chemicals, plastics
2019-20	16.61	-0.8%	65.26	-7.2%	-48.65	Iron ore, cotton, copper, organic chemicals	Electronics, machinery, organic chemicals, plastics
2020-21	21.18	+27.5%	65.21	-0.1%	-44.03	Iron ore, cotton, copper, organic chemicals	Electronics, machinery, organic chemicals, plastics
2021-22	21.92	+3.5%	94.16	+44.5%	-72.24	Iron ore, cotton, copper, organic chemicals	Electronics, machinery, organic chemicals, plastics
2022-23	15.4	-29.7%	98.51	+4.6%	-83.11	Iron ore, cotton, copper, organic chemicals	Electronics, machinery, organic chemicals, plastics
2023-24	16.65	+8.1%	101.75	+3.3%	-85.1	Iron ore, cotton, copper, organic chemicals	Electronics, machinery, organic chemicals, plastics
2024-25	14.25	-14.4%	113.45	+11.5%	-99.2	Ores/slag/ash ($1.94B), mineral fuels ($1.27B), organic chemicals ($1.26B), machinery ($1.16B)	Electrical machinery ($38.02B), nuclear reactors/machinery ($25.92B), organic chemicals ($11.47B), plastics ($6.33B)
2025-26 (Apr-Sep)	9.5 (est.)	+5.6% YoY (partial)	60.2 (est.)	+2.4% YoY (partial)	-50.7 (partial)	Iron ore, cotton, copper, organic chemicals	Integrated circuits ($941M Jul), telephones ($839M Jul), computers ($686M Jul)

Additional Info

(a) Trade deficit widened to a record $99.2B in FY2024-25, driven by dumping in electronics and solar cells, with March 2025 imports jumping 25% to $9.7B.

(b) Imports from China escalated from $60.4B in FY2014-15 to $113-127B in 2024, the figures refer to total imports, not just electronics (electronics were ~$38-44B in 2024). This underscores assembly dependencies.

US-India Goods Trade

Year	India’s Exports to US	% Change (Exports)	India’s Imports from US	% Change (Imports)	Trade Balance (Exports – Imports)	Major Goods Exported by India to US	Major Goods Imported by India from US
2014	42.4	–	21.5	–	+20.9	Pharmaceuticals, gems/jewelry, textiles, machinery	Aircraft, machinery, optics, electrical equipment
2015	44.8	+5.7%	21.5	0.0%	+23.3	Pharmaceuticals, gems/jewelry, textiles, machinery	Aircraft, machinery, optics, electrical equipment
2016	45.2	+0.9%	22.0	+2.3%	+23.2	Pharmaceuticals, gems/jewelry, textiles, machinery	Aircraft, machinery, optics, electrical equipment
2017	48.6	+7.5%	25.7	+16.8%	+22.9	Pharmaceuticals, gems/jewelry, textiles, machinery	Aircraft, machinery, optics, electrical equipment
2018	54.4	+11.9%	33.1	+28.8%	+21.3	Pharmaceuticals, gems/jewelry, textiles, machinery	Aircraft, machinery, optics, electrical equipment
2019	57.7	+6.1%	35.5	+7.3%	+22.2	Pharmaceuticals, gems/jewelry, textiles, machinery	Aircraft, machinery, optics, electrical equipment
2020	51.6	-10.6%	28.9	-18.6%	+22.7	Pharmaceuticals, gems/jewelry, textiles, machinery	Aircraft, machinery, optics, electrical equipment
2021	76.1	+47.5%	43.3	+49.8%	+32.8	Pharmaceuticals, gems/jewelry, textiles, machinery	Aircraft, machinery, optics, electrical equipment
2022	78.3	+2.9%	47.4	+9.5%	+30.9	Pharmaceuticals, gems/jewelry, textiles, machinery	Aircraft, machinery, optics, electrical equipment
2023	77.5	-1.0%	41.9	-11.6%	+35.6	Pharmaceuticals, gems/jewelry, textiles, machinery	Aircraft, machinery, optics, electrical equipment
2024	87.3	+12.6%	41.5	-0.9%	+45.8	Pharmaceuticals ($10.89B), gems ($10.19B), textiles	Aircraft, machinery, optics, electrical equipment
2025 (Apr-Sep)	38.7 (est.)	+3.4% YoY (partial)	22.8 (est.)	+4.5% YoY (partial)	+15.9 (partial)	Pharmaceuticals, gems/jewelry, textiles, machinery	Aircraft, machinery, optics, electrical equipment

Additional info: Bilateral goods trade reached $129B in 2024, with US exports to India at $41.5B (+3.0%) and imports from India at $87.3B (+4.5%), yielding a $45.8B deficit for the US. In FY2025, bilateral trade hit $132.2B, up from $119.71B in FY2024 (note FY vs. calendar basis).

China-India Services Trade

Year	India’s Services Exports to China	% Change	India’s Services Imports from China	% Change	Trade Balance (Exports – Imports)	Major Services
2014	1.2	–	0.8	–	+0.4	IT, tourism, transport
2015	1.3	+8.3%	0.9	+12.5%	+0.4	IT, tourism, transport
2016	1.4	+7.7%	1.0	+11.1%	+0.4	IT, tourism, transport
2017	1.5	+7.1%	1.1	+10.0%	+0.4	IT, tourism, transport
2018	1.6	+6.7%	1.2	+9.1%	+0.4	IT, tourism, transport
2019	1.7	+6.3%	1.3	+8.3%	+0.4	IT, tourism, transport
2020	1.5	-11.8%	1.1	-15.4%	+0.4	IT, tourism, transport
2021	1.8	+20.0%	1.4	+27.3%	+0.4	IT, tourism, transport
2022	2.0	+11.1%	1.5	+7.1%	+0.5	IT, tourism, transport
2023	2.1	+5.0%	1.6	+6.7%	+0.5	IT, tourism, transport
2024	2.3	+9.5%	1.8	+12.5%	+0.5	IT, tourism, transport
2025 (Apr-Sep)	1.2 (est.)	+4.3% YoY (partial)	0.9 (est.)	+5.6% YoY (partial)	+0.3 (partial)	IT, tourism, transport

Services trade remains modest, with India’s surplus at ~$0.5B annually, far below goods imbalances. Total China services trade value grew from ~$2B in 2014 to ~$4.1B in 2024.

Note: “Data is estimated; official bilateral services breakdowns are scarce.”

US-India Services Trade

Year	India’s Services Exports to US	% Change	India’s Services Imports from US	% Change	Trade Balance (Exports – Imports)	Major Services
2014	25.0	–	15.0	–	+10.0	IT/BPM, financial, telecom
2015	27.0	+8.0%	16.0	+6.7%	+11.0	IT/BPM, financial, telecom
2016	29.0	+7.4%	17.0	+6.3%	+12.0	IT/BPM, financial, telecom
2017	31.0	+6.9%	18.0	+5.9%	+13.0	IT/BPM, financial, telecom
2018	33.0	+6.5%	19.0	+5.6%	+14.0	IT/BPM, financial, telecom
2019	35.0	+6.1%	20.0	+5.3%	+15.0	IT/BPM, financial, telecom
2020	30.0	-14.3%	18.0	-10.0%	+12.0	IT/BPM, financial, telecom
2021	36.0	+20.0%	22.0	+22.2%	+14.0	IT/BPM, financial, telecom
2022	38.0	+5.6%	23.0	+4.5%	+15.0	IT/BPM, financial, telecom
2023	40.0	+5.3%	36.1	+57.0%	+3.9	IT/BPM, financial, telecom
2024	41.6	+4.0%	41.8	+15.9%	-0.2	IT/BPM, financial, telecom
2025 (Apr-Sep)	21.0 (est.)	+1.9% YoY (partial)	21.2 (est.)	+1.4% YoY (partial)	-0.2 (partial)	IT/BPM, financial, telecom

Additional info: US-India services trade was nearly balanced at ~$83.4B in 2024, with India’s exports at $41.6B and imports at $41.8B (+15.9% for US exports). April-September 2025 saw subdued growth amid NTBs.

Comparative Roles In The Indian Economy

From 2014 to September 2025, China emerged as India’s dominant import partner, fueling a kit-and-assemble economy where domestic value addition (DVA) in electronics and smartphones started at 2% in 2014 and reached only 15-23% by 2024-25, with 70-85% of smartphone parts imported.

Bilateral trade ballooned from ~$72B in 2014 to $115B in 2023, but with deficits swelling to $99.2B by 2024 due to electronics and machinery inflows. This dependency exacerbated India’s kit-and-assemble economy, where sectors like automobiles achieved 70% DVA by 2014 but EVs lagged at 20-40% pre-2021, reliant on Chinese batteries and motors. In contrast, the US provided a more balanced partnership, with goods trade growing from ~$64B in 2014 to $132.2B in FY25, and services nearly even at ~$83B in 2024. India’s surplus in services (IT/BPM) offset goods deficits, but NTBs like visa restrictions eroded this edge.

Historical trends show China’s role amplifying India’s import vulnerabilities, with electronics production rising from $23-31B in 2014-15 to $133-138B in 2024-25, yet mostly assembly. US ties bolstered exports in pharma and gems, growing 82% from 2014 to 2024, but tariffs hit 55-66% of goods exports. Overall GDP grew nominally from ₹112 lakh crore in 2014 to ₹350 lakh crore in 2025, but real growth averaged 5%, fudged via overstated consumption (56.5% of GDP in 2024-25) and ignored informal collapses. Poverty reduction claims of lifting 135-270M since 2015 mask fudged metrics, with 56% (81 crore) reliant on rations under the $3/day IPL.

Imports From China For Common People: Daily Essentials And Consumer Goods

From 2014 to 2025, a significant portion of India’s imports from China catered to the masses, comprising affordable consumer goods that permeated everyday life. These items, often low-cost and mass-produced, filled gaps in domestic production, but their influx exacerbated trade deficits and stifled local industries. Key categories included textiles, medicines, toys, footwear, plastics, and household items, collectively accounting for 20-30% of total imports annually, rising from approximately $12-15 billion in 2014 to $25-35 billion by 2024.

Textiles And Apparel: China’s dominance in cotton yarns, fabrics, and ready-made garments supplied cheap clothing to India’s burgeoning middle and lower classes. Imports grew from $2.5 billion in 2014 to $5.8 billion in 2024, with items like synthetic fibers and dyed fabrics flooding markets. These were staples for daily wear, school uniforms, and household linens, enabling affordability amid stagnant wages. However, this dependency led to the closure of thousands of small Indian weaving units, with data fudges overstating domestic textile output by including re-exported Chinese yarns as “Indian-made.” (India-China trade dynamics in cotton and textiles).

Medicines And Pharmaceutical Intermediates: Active pharmaceutical ingredients (APIs) and bulk drugs from China formed the backbone of India’s generic medicine supply, crucial for treating common ailments like fever, infections, and chronic conditions. Imports of APIs escalated from $2.4 billion in 2014 to $3.84 billion in 2023-24, with China supplying 65-70% of India’s total API needs. Paracetamol (91% from China), antibiotics like penicillin, and intermediates for diabetes drugs were ubiquitous in pharmacies and households. This reliance ensured low-cost healthcare for the masses but exposed vulnerabilities during supply disruptions, such as the 2020 COVID-19 shortages. Official claims of “self-reliance” masked this by inflating DVA figures, ignoring that 90% of key APIs lacked domestic alternatives.

Toys, Footwear, And Plastics: These everyday items democratised access to leisure and utility products. Toy imports from China, including plastic dolls, puzzles, and electronic gadgets, rose from $0.8 billion in 2014 to $2.1 billion in 2024, delighting children in urban slums and rural homes alike. Footwear, such as synthetic shoes and sandals, surged from $1.2 billion to $3.5 billion, providing durable options for daily commutes. Plastics and articles thereof, used in kitchenware, packaging, and household goods, increased from $1.8 billion in 2017 to $2.4 billion in 2018, with cumulative growth to $4-5 billion by 2024. These imports lowered living costs but contributed to environmental degradation and job losses in informal sectors, with data manipulations underreporting import volumes to project “green growth.”

These consumer imports, while enhancing quality of life for the average Indian—where 56% of the population (81 crore) relies on subsidised rations—widened the trade deficit, reaching -99.2 billion in FY 2024-25. They reflected a consumption-driven economy, but fudged poverty metrics (claiming 135-270 million lifted out since 2015) obscured how these cheap goods masked declining real incomes. (Unmasking India’s poverty reduction mirage)

Imports From China For Elites, Corporations, Government, And Infrastructure: Minimal Impact On Common Lives

In contrast, a larger share of imports—40-50% annually—targeted elite consumption, corporate operations, government projects, and infrastructure, with limited benefits for the common populace. These included heavy machinery, electrical equipment, steel, chemicals, and solar panels, ballooning from $25-30 billion in 2014 to $50-60 billion by 2024. Such imports fueled elite-driven growth, often in export-oriented zones or urban megaprojects, while bypassing rural and informal economies.

Machinery And Electrical Equipment: Dominating imports at $31.35 billion in FY24 (up from $18 billion in 2014), these included industrial boilers, nuclear reactors, and automation tools for factories and power plants. Primarily used by large corporations like Tata and Reliance, they supported elite manufacturing hubs but displaced labor in small enterprises. Government infrastructure projects, such as smart cities, absorbed 20-25% of these, yielding minimal job creation for the masses.

Steel And Chemicals: Steel imports grew from $3.2 billion in 2014 to $6.5 billion in 2024, feeding construction booms in high-rises and highways—projects benefiting urban elites and contractors. Organic chemicals ($15.8 billion cumulative in pharma-related, but industrial variants for dyes and fertilizers) supported corporate agriculture and manufacturing, with little direct impact on small farmers.

Solar Panels And Renewable Equipment: Imports of solar cells and modules hit $1.3 billion in Q1 2025 (down slightly due to tariffs), with cumulative $10-15 billion since 2014. While promoting green energy, 70% of India’s solar capacity relies on Chinese equipment for government-backed projects, enriching utilities and elites via subsidies, but offering scant electricity access improvements for rural poor.

These imports perpetuated inequality, with top 1% capturing 22.6% of income, while data fudges exaggerated infrastructure’s GDP contribution (overstated at 8-10% annually). (Unraveling GDP illusions)

Sectoral Deep Dive: Automobiles, Pharmaceuticals, Electronics, Smartphones, And Semiconductors

In sectors, automobiles saw passenger vehicle sales up 10.6% (3.89M to 4.30M units) from 2023-2025, but debt-fueled (household leverage at 42% GDP) and assembly-dominant, with EV DVA at 55-65% for Ola Electric in 2025, blending 30-40% domestic cells with 60-70% imports. Pharmaceuticals exports to the US hit $10.89B in 2024, but face exemptions amid tariffs. Electronics and smartphones remain import-heavy from China, with mobile production from $2.3B to $51-66B (2014-2025), but DVA low at 15-23%. Semiconductors embody India’s semiconductor ambitions, shifting from assembly to fabrication dreams, yet stuck at low DVA due to global IP dependencies.

Automobiles

Auto component imports from China constituted 26.6% of India’s total ($1.91 billion of $7.17 billion in FY25), up from 15-20% in 2014. Key items: engines, transmissions, and EV batteries/motors, with DVA at 55-65% for EVs like Ola Electric (blending 30-40% domestic cells with 60-70% imports). This assembly culture drove sales growth (10.6% from 2023-25) but relied on debt (75-80% credit-financed), risking defaults amid household leverage at 42% GDP. Pure manufacturing remains low, with vulnerabilities to Chinese supply chains. (Evolution of domestic value addition in India’s automotive sector The illusion of self-reliance: Ola Electric’s DVA journey Debt-fueled drive in India’s automobile sector India’s auto assembly revolution)

Pharmaceuticals

China supplied 65-70% of APIs, with imports from $2.4 billion (2014) to $3.84 billion (2023-24). Critical for generics (analgesics, antimicrobials), this dependency hit 90%+ for drugs like ibuprofen. While enabling affordable meds, it exposed risks; fudged self-reliance claims ignore that two-thirds of bulk drugs lack alternatives, with exports masking import reliance.

Electronics

Electronics imports from China rose from $15-20 billion (2014) to $44.15 billion (2024), including components for TVs, appliances. Production hit $133-138 billion by 2024-25, but DVA at 15-23%, with 70-85% parts imported. This fueled consumer access but perpetuated assembly over innovation.

Smartphones

Components imports dominated, with 70-85% from China; production from $2.3 billion (2014) to $51-66 billion (2025), but imports dropped from $8 billion (2014-15) to $0.43 billion (2024-25) due to assembly shifts. India overtook China in US exports (44% share in Q2 2025), yet DVA low, reliant on Chinese BOM inputs.

Semiconductors And Chips

Imports grew 92% in recent years, with 70% from China/Hong Kong, valued at $38 billion (2024) projected to $105 billion by 2030. Mission initiatives aim for fabrication, but current reliance on Chinese chips for electronics and autos highlights strategic risks, with fudged “ecosystem” claims ignoring IP dependencies.

Future Trends And Projections

Amid 50% US tariffs (affecting textiles, gems), India’s goods exports could drop 10-15% in 2026, exacerbating 2025 trade troubles. Services face $15-25B losses in 2025 from NTBs, including May 2025 visa restrictions on travel agencies, August-September changes narrowing interview waivers, and the $100k H-1B fee, hitting IT margins by 100 basis points. Aligned exemptions may spare generic pharma for the time being, but H-1B hikes could reduce remittances by 5-10%, worsening domestic consumption decline (down to 55% GDP share in 2025-26). With China tensions easing amid US pressures, imports may stabilise, but assembly culture persists, limiting pure manufacturing (100% Indian elements) to <10% in EVs/smartphones.

Projections: Real GDP growth at 2.5-4% in 2025-26, per GDP illusions, amid poverty reduction mirage and elite gains (top 1% capturing 22.6% income). Auto sector risks from debt (resilience via auto assembly revolution but 75-80% credit-financed sales) could lead to defaults. Net FDI hit rock-bottom in 2025, per FDI conundrum, signaling broader retreat. A DII Bubble (DIIs at 17.62% market share, ₹5.13 lakh crore invested in 2025) risks collapse by 2026. (India’s economic condition amid trade tensions India’s services trade surge and US tariff dynamics US-India bilateral trade analysis Navigating 2025 H-1B visa changes India’s economy looks good on paper Non-tariff barriers on Indian services by US Domestic consumption decline in India)

In sum, India’s China imports from 2014-2025 reveal a dual economy: consumer goods sustaining the masses amid fudged progress, and industrial inputs enriching elites. Future trends, amid tariffs and NTBs, portend stabilised imports but persistent dependencies, with real GDP growth at 2.5-4% in 2025-26.

India’s semiconductor sector stands at a pivotal juncture, embodying the nation’s broader quest for technological sovereignty under the “Atmanirbhar Bharat” (Self-Reliant India) banner. Launched in 2021 with the India Semiconductor Mission (ISM), the government’s ambitious push aims to transform India from a near-total importer of chips—dependent on global giants like Taiwan, South Korea, and China—into a global hub for design, assembly, and manufacturing. With projections estimating the domestic market to swell from $45-50 billion in 2025 to $100-110 billion by 2030, the stakes are high. Yet, as discussions on platforms like X (formerly Twitter) and analyses from think tanks such as ODR India reveal, the narrative is one of bold claims clashing with stark realities: robust gross foreign direct investment (FDI) inflows mask plummeting net inflows, assembly operations dominate over true fabrication, and verifiable commercial products remain elusive despite 2025 production starts.

This article dissects the semiconductor landscape from 2020 to 2025, bifurcating assembly (back-end processes like packaging and testing) from full manufacturing (front-end wafer fabrication). Drawing on the ODR India report on India’s “FDI conundrum”—where gross FDI rebounded to $81 billion in FY 2024-25 amid PLI incentives, but net inflows cratered to $0.35 billion due to $51 billion in repatriations—we probe the veracity of government assertions. X threads echo this tension, celebrating milestones like ISRO’s Vikram chip while questioning ecosystem gaps. We also explore FDI trends, independent testing timelines, and the elusive “verifiable final product” for third-party commercial use.

Assembly vs. Manufacturing: A Bifurcated Reality (2020-2025)

Semiconductor production spans front-end (wafer fabrication, where silicon wafers are etched into chips) and back-end (assembly, testing, marking, and packaging or ATMP/OSAT). India’s journey since 2020 has skewed heavily toward the latter, leveraging lower barriers to entry and PLI incentives. Full manufacturing—requiring $10-20 billion fabs and ultra-pure supply chains—remains nascent, with actual capacity under 0.1% of global wafer fabrication in 2025.

From 2020-2022, India focused on electronics assembly (e.g., mobiles via PLI 1.0), achieving 70% value addition in devices like refrigerators but only 2-8% in components. The ISM’s 2021 launch shifted gears, approving OSAT units first. By 2023, assembly capacity ramped up: Tata’s Assam OSAT (48 million chips/day targeted for 2025) and CG Power-Renesas’ Gujarat facility (pilot OSAT operational by July 2025). Full fabs lagged, with SCL Chandigarh’s legacy nodes (180nm) producing niche chips like ISRO’s IRIS/SHAKTI.

In 2024-2025, bifurcation sharpened: 10 ISM-approved projects (total $18.23 billion) include 5 OSAT/ATMP (e.g., Micron’s Gujarat ATMP, first chips by late 2025) vs. 5 fabs (e.g., Tata-PSMC’s Dholera, 50,000 wafers/month by 2026). X users hail this as a “revolution,” but ODR notes PLI’s $25 billion incentives fueled gross inflows without addressing net retention, risking “shallow” manufacturing.

Year	Assembly Capacity (Key Projects/Output)	% of Total Capacity	Full Manufacturing Capacity (Key Projects/Output)	% of Total Capacity	Notes on Veracity
2020-21	Minimal; SPECS scheme launches incentives for ATMP (25% capex). Electronics assembly at 30% value add.	~100%	SCL Chandigarh: Legacy nodes (<1% global share). No new fabs.	~0%	Claims of “hub” status overstated; imports >$100B projected by 2025.
2021-22	PLI 2.0 approves OSAT; Tata Assam planning (48M chips/day).	95%+	ISM launches; first fab approvals (e.g., Vedanta-Foxconn, stalled).	<5%	Gross FDI up 3.4%, but net down; assembly hype ignores fab delays.
2022-23	CG-Renesas Gujarat OSAT ($0.92B); Micron ATMP announced.	90%	Tata-PSMC fab ($11B) approved; 0 wafers operational.	10%	Production claims unverified; X debates “assembly trap.”
2023-24	Micron Gujarat SEZ (6.33M chips/day); HCL-Foxconn UP ($0.45B).	85%	Dholera fab construction starts; SCL produces IRIS chip.	15%	4 units approved; net FDI -16.7%, questioning sustainability.
2024-25	5 OSAT operational/pilot (e.g., Renesas mid-2026 chips); Tata Assam live. Total: ~100M chips/year.	80%	First commercial fab output (28-90nm) by end-2025; Vikram chip qualified.	20%	Claims of “commercial start” by Modi; reality: test/pilot phase, no mass scale.
Cumulative (2020-25)	~$5-7B invested; 70-80% of approved capacity.	85%	~$13-15B (e.g., 10 projects); <0.1% global wafers.	15%	ODR: Gross $81B total FDI masks net $0.35B; semiconductors ~2-3% share, vulnerable to outflows.

In 2025, assembly constitutes ~80% of capacity (back-end focus for autos/EVs), vs. 20% full manufacturing (legacy nodes for defense/space). X sentiment: Optimistic on jobs (1M by 2026) but skeptical of “pure” manufacturing claims.

Government Claims vs. Veracity: Hype Meets Hurdles

The Modi administration touts 2025 as a “milestone year,” with PM Modi announcing commercial production by year-end at Semicon India 2025, showcasing ISRO’s Vikram 32-bit processor. ISM claims ₹76,000 crore ($9B) outlay, 97% committed ($7.17B), enabling 10 projects and 15,700 jobs. PLI/SPECS incentives (up to 50% capex for fabs) are credited for a 13.6% gross FDI rebound.

Reality Check: ODR exposes the “conundrum“—gross figures dazzle, but net FDI at 0.01% GDP signals capital flight, eroding long-term capacity buildout. Fully manufactured chips? Vikram/IRIS are qualified for space (harsh conditions), but commercial scale is pilot-only; no third-party verifiable mass production yet. X threads question: “Assembly or real fabs?” amid stalled projects like Vedanta-Foxconn. Veracity: Partially true—progress in assembly (value add in electronics)—but full chips lag, with imports still >$100B annually.

FDI In Semiconductors: Gross Surge, Net Mirage (2020-2025)

Semiconductors fall under DPIIT’s “Computer Software & Hardware,” attracting 15% of cumulative FDI equity ($160B since 2000). Post-ISM, inflows targeted chips: Cumulative approved ~$18-20B (70% private).

Fiscal Year	Gross FDI in Semiconductors (USD Bn)	YoY % Change	Net FDI in Semiconductors (USD Bn)*	YoY % Change	Key Drivers/Notes
2020-21	0.5	+10%	0.3	-5%	SPECS launch; assembly focus. Total gross FDI: $82B.
2021-22	0.8	+60%	0.5	+67%	ISM/PLI approvals; Micron/Tata announcements.
2022-23	1.2	+50%	0.7	+40%	OSAT inflows; net drag from outflows.
2023-24	2.0	+67%	1.0	+43%	4 projects approved; $71.3B total gross.
2024-25	3.0 (est.)	+50%	0.1	-90%	$81B gross total, but net $0.35B overall; semis ~3% share, hit by repatriation.
Cumulative	7.5	–	2.6	–	~2-3% of total FDI; ODR: Net collapse risks “hollow” growth.

*Net = Gross minus repatriation/outflows; sector est. from 15% hardware share, adjusted for semis subset. In 2025, cumulative net ~$2.6B reflects ODR’s broader trend: High gross ($390B total 2020-25) vs. low net ($144B), with semis vulnerable to U.S. tariffs/geopolitics. X buzz: “FDI staggering, but retention key.”

ISRO/Government Chips: Path To Independent Verification

ISRO’s SCL has pioneered: IRIS (SHAKTI-based, 64-bit RISC-V for space, booted Feb 2025) and Vikram (32-bit, qualified for launch vehicles, presented Sep 2025). These mark India’s first “fully indigenous” chips, fabricated domestically (180nm node).

Testing: SCL/ISRO conducted in-house validation (electrical, fault tolerance). Independent verification? National (e.g., IIT Madras collaboration) ongoing; international possible via iCET (U.S.-India pact for joint R&D/testing) by late 2025, or SEMI standards at Semicon India. Flight tests (e.g., IRIS in ISRO missions) by Q4 2025 could enable third-party audits; full commercial certification (UL/ISO) targeted for 2026. X: “Breakthrough, but global scrutiny needed.”

Actual Production In 2025: Verifiable Commercial Products And Third-Party Use

2025 sees “starts,” not scale: CG Power’s Gujarat OSAT launches August 2024 (first operational back-end); Renesas pilot by July 2025; Tata Assam by year-end (48M units/day, but assembly-focused). Verifiable finals? Micron’s ATMP yields first “Made in India” chips (DRAM/NAND) by December 2025, Bosch-Tata collab for auto chips mid-2026. Third-party use: ISRO’s Vikram for defense (qualified, but govt-only initially); commercial via PLI exports by Q4 2025, verifiable via SEMI audits.

ODR/X Consensus: 2025 production is real but assembly-heavy (80% vs. 20% pure manufacturing), with net FDI woes delaying ecosystem maturity. True commercial viability? 2026-27, per Moody’s, if reforms sustain.

Conclusion: Bridging Claims And Capacity

India’s semiconductor saga is a tale of momentum meets moderation. Gross FDI and PLI have ignited assembly (85% cumulative capacity), but net inflows’ rock-bottom ($0.35B FY25) underscore ODR’s warning: Without curbing outflows, the “powerhouse” remains aspirational. X optimism—$110B market, 1M jobs—must temper with reality: Full manufacturing at 15-20%, verifiable products by late 2025. Independent testing (national/international) for ISRO chips could catalyze trust by Q4 2025, paving third-party commercial paths. As global chains diversify from China, India’s 20% design talent edge positions it well—but only if net FDI stabilises and fabs scale. The revolution is underway; verifiability will define its legacy.

The bilateral trade relationship between India and China has been a cornerstone of global economic interactions, characterized by rapid growth in imports from China to India, stagnant exports in the opposite direction, and a persistently widening trade deficit. From 2014 to 2025, India’s imports from China surged from approximately $58 billion to $127 billion, while exports to China hovered between $12 billion and $21 billion, peaking in 2020 before settling around $15 billion in 2024. This imbalance, exacerbated by India’s reliance on Chinese electronics, machinery, and chemicals, contrasts with its exports of raw materials like iron ore, cotton, and seafood.

The cotton and textile sector exemplifies this dynamic, where India simultaneously imports raw cotton to bolster its domestic industry while exporting processed yarn to China, acting as a key processing hub in global supply chains. Recent policy shifts, such as India’s duty cuts on U.S. cotton imports, further highlight efforts to navigate trade tensions and enhance competitiveness.

Amid these trends, criticisms have emerged regarding the effectiveness of Prime Minister Narendra Modi’s self-reliance initiatives like Atmanirbhar Bharat, Swadeshi, and Made in India, with some sources alleging these are mere rhetoric masking increased dependency on China. This article explores these trends, drawing on trade data, policy analyses, and sector-specific insights up to September 2025, incorporating perspectives on policy shortcomings and their role in perpetuating trade imbalances.

Overall Trade Trends Between India And China

India’s trade with China has grown asymmetrically over the past decade, with imports dominating the narrative. The trade deficit ballooned from $46 billion in 2014 to over $112 billion in 2024, driven by India’s demand for value-added goods from China. Key imports include electronics (e.g., smartphones and components), machinery, and organic chemicals, which constitute a significant portion of the bilateral trade. In contrast, India’s exports remain commodity-heavy, with cotton playing a pivotal role despite fluctuations.

The following table summarises the bilateral trade data, illustrating the import surge and export stagnation:

Year	Imports from China (USD Bn)	% Change	Exports to China (USD Bn)	% Change
2014	58	–	12	–
2015	71	+22%	12	0%
2016	61	-14%	9	-25%
2017	76	+25%	13	+44%
2018	70	-8%	17	+31%
2019	65	-7%	17	0%
2020	65	0%	21	+24%
2021	97	+49%	21	0%
2022	102	+5%	14	-33%
2023	99	-3%	16	+14%
2024	127	+28%	15	-6%
2025 (up to Sept)	~75	+15% (proj.)	~10	+10% (proj.)

Trade Surplus/Deficit Between India And China

The trade imbalance has resulted in a consistent deficit for India, which has widened significantly since 2014. This deficit reflects India’s growing dependency on Chinese imports despite efforts to promote domestic manufacturing. The table below details the annual trade deficit (calculated as imports minus exports), highlighting the absence of any surplus and the escalating gap.

Year	Trade Deficit (USD Bn)	% Change from Previous Year
2014	46	–
2015	59	+28%
2016	52	-12%
2017	63	+21%
2018	53	-16%
2019	48	-9%
2020	44	-8%
2021	76	+73%
2022	88	+16%
2023	83	-6%
2024	112	+35%
2025 (up to Sept)	~65	+8% (proj.)

The Paradox Of Cotton Trade: Importing While Exporting

A striking aspect of India-China trade is India’s dual role in the cotton market. As the world’s second-largest cotton producer (behind China), India generates about 23-25% of global output, with domestic production reaching around 24-29 million bales annually from 2015 to 2025. Yet, it imports raw cotton—primarily extra-long staple (ELS) varieties like Pima from the U.S., Brazil, and Australia—to address quality gaps in its medium-staple dominant harvest (Gossypium hirsutum, 25-32 mm staple length). These imports, which surged 324-499% in early 2025, fill seasonal shortages caused by pests (e.g., pink bollworm), erratic monsoons, and declining yields (down to 436 kg/ha in 2024).

Simultaneously, India exports surplus cotton, often as processed yarn, to China, which values it for cost-competitiveness and suitability in mass production. Indian yarn is 10-20% cheaper than alternatives, with strong luster and spinability, making it ideal for China’s textile factories. Exports to China spiked 411% in mid-2023, reaching 248,000 tons valued at $800-1,000 million. This dynamic is not a sign of inefficiency but a reflection of global specialisation: India consumes 85-90% of its cotton domestically for its $200 billion textile industry, which employs over 45 million people, while exporting value-added products to meet China’s demand amid its raw cotton import quotas and tariffs.

Duty Cuts On U.S. Cotton: Enabling Profitable Re-Exports

India’s policy of periodic duty exemptions on cotton imports has been instrumental in turning imported raw fiber into profitable exports. From 2014 to 2021, imports were largely duty-free, supporting the textile sector. An 11% duty was introduced in October 2021 to protect farmers, but exemptions in 2022 (April-October) and 2025 (August-December) reversed this amid U.S. tariffs on Indian apparel (up to 50%). These cuts reduce landed costs by 5-10%, allowing India to import cheap U.S. cotton, process it into yarn (adding 20-30% value), and re-export to China.

In 2025, U.S. cotton imports reached $234 million (FY25 partial), potentially yielding $300-500 million in yarn export profits to China. However, this risks local price depression below the minimum support price (INR 7,710/100 kg), impacting farmers and the Cotton Corporation of India (CCI) with estimated losses of INR 700 crore. Critics argue that such policies, while aimed at self-reliance, inadvertently exacerbate dependencies, as seen in the broader trade context where U.S. tariffs (e.g., 25% imposed by former President Trump) threaten India’s $45.7 billion trade surplus with the U.S. in 2024, potentially leading to losses of around $46 billion that primarily affect elite intermediaries rather than the wider economy.

Year	Import Duty Status	Raw Cotton Imports from US ($M)	Cotton Yarn Exports to China ($M)
2014	Duty Free	N/A	~1,900
2015	Duty Free	N/A	N/A
2016	Duty Free	N/A	N/A
2017	Duty Free	~300	N/A
2018	Duty Free	N/A	N/A
2019	Duty Free	N/A	N/A
2020	Duty Free	N/A	N/A
2021	11% imposed Oct	N/A	N/A
2022	Exempt Apr-Oct	N/A	N/A
2023	11%	N/A	~800-1,000
2024	11%	199	430
2025 (partial)	Exempt Aug-Dec	234	N/A (proj. dip 66% in FY25)

India As A Global Processing Hub In Cotton

India’s position as a “processing hub” involves importing specialised raw materials to enhance domestic output and exporting surplus value-added products. With over 50 million spindles, India processes 1-2 million imported bales annually into yarn, exporting $1.5-2 billion worth to China yearly—14% of its yarn exports—helping offset the trade deficit by 1-2%. This model thrives on China’s quotas on raw cotton, making Indian yarn a tariff-free alternative amid U.S.-China tensions.

Year	Domestic Production (000 480 lb bales)	Total Raw Cotton Imports ($M)	Cotton Yarn Exports to China ($M)	Trade Deficit with China ($B)
2014	N/A	N/A	~1,900	46
2015	25,900	N/A	N/A	59
2016	27,000	N/A	N/A	52
2017	29,000	N/A	N/A	63
2018	26,000	N/A	N/A	53
2019	28,500	N/A	N/A	48
2020	27,500	N/A	N/A	44
2021	24,300	N/A	N/A	76
2022	26,300	1,703	N/A	88
2023	25,400	~1,400	~800-1,000	83
2024	24,000	~590	430	112
2025 (partial)	24,000	~1,200	N/A	~65

Imports Of Final Textile Products From China

Despite its textile prowess, India imports final products like ready-made garments and home textiles from China, valued at $1.8-4.0 billion annually from 2014 to 2024. These imports, under HS codes 61-63, meet demand for affordable synthetics and designs, with China’s share at 40-42% of India’s total textile imports. Growth was volatile, dipping in 2020 due to COVID-19 but rebounding 59% in 2021. By September 2025, imports reached $2.5 billion, projected at $4.2-4.5 billion for the year, amid concerns over dependency and calls for anti-dumping measures.

Year	Imports from China (USD Bn)	% Change
2014	1.8	–
2015	2.2	+22%
2016	1.9	-14%
2017	2.4	+26%
2018	2.8	+17%
2019	2.5	-11%
2020	2.2	-12%
2021	3.5	+59%
2022	3.8	+9%
2023	3.2	-16%
2024	4.0	+25%
2025 (up to Sept)	2.5	+4% (proj.)

Criticisms Of Self-Reliance Policies And Increased Dependency

Modi’s flagship initiatives—Swadeshi, Atmanirbhar Bharat, and Made in India—have faced sharp criticism for being empty rhetoric (Jumlabaazi) that masks policy failures and deceit. Launched prominently during the COVID-19 era, these slogans promised reduced foreign dependency, yet the trade deficit with China has increased annually since 2014, reaching $112 billion in 2024. Critics argue that superficial bans on Chinese goods are bypassed by rerouting them through warehouses controlled by government-aligned elites (“Govt Buddies“), who then re-export to markets like the EU and UK for profit, benefiting a select few while small businesses and MSMEs suffer.

Two additional inputs underscore these concerns: First, India’s $45.7 billion trade surplus with the U.S. in 2024 is at risk from U.S. tariffs (e.g., 25% under Trump), potentially erasing around $46 billion in value that critics claim disproportionately affects elite intermediaries rather than boosting broad-based GDP growth. Second, despite self-reliance rhetoric, economic distress persists, with claims that 81 crore Indians rely on government rations (5 kg per person) and 100 crore are hand to mouth, highlighting a failure to build domestic production capabilities and counter Chinese market flooding.

Conclusion: Balancing Trade And Self-Reliance

The India-China cotton and textile trade from 2014 to 2025 reveals a complex interplay of comparative advantages, policy interventions, and global disruptions. While India’s role as a processing hub generates employment and forex, the growing deficit and import dependency on final products underscore the need for diversification, innovation, and stronger domestic value chains. Criticisms of Modi’s self-reliance initiatives suggest that without addressing underlying deceit and elite favoritism, these efforts may perpetuate rather than resolve imbalances. As of September 2025, ongoing U.S. tariff impacts and duty exemptions signal potential shifts, but sustainable growth will require tackling farmer vulnerabilities, MSME support, and genuine reductions in Chinese dependency to make slogans like Atmanirbhar Bharat a reality. But for the time being, Indians can be fooled with useless jumlas like GST Bachat Utsav.

This article is about how US tariffs are hurting India’s trade, jobs, and growth in 2025. All info comes from trusted sources.

Trade With The US: Less Money Coming In

India sells $73 billion to the US this year—$45 billion in goods like clothes and chemicals, $28 billion in services like IT help. India buys $37 billion back, so we have a $36 billion extra (surplus). But tariffs cut goods sales by 43%, making it smaller than planned.

Worldwide, India sells $419 billion and buys $470 billion, leaving a $51 billion gap (deficit). Services make extra money, but goods lose it.

Tariffs Slow India’s Growth

Tariffs are extra costs on Indian goods in the US. They could lower India’s growth by 0.5 to 1 point in 2025. Without them, growth would be 6-6.5%. With them, it’s 5-5.5%. (This means subtracting points, not a small percent—easy to mix up.)

Sales to the US dropped from $11 billion in March to $7 billion in September. This might cost 1-2 million factory jobs, plus 3-5 million related ones. Unemployment could hit 6.5%. Stocks fell 8-10% in August, losing $500-700 billion. Main indexes are down a bit this year.

The rupee is weaker (88 to 1 USD, down 5%). This helps sell more exports (up 2-3%), but makes buying imports costlier and slows spending.

Data splits before and after tariffs started on September 8. Extra rules could cut services sales by 15-20%, losing $6 billion in half a year. Growth isn’t fair—many people still face poverty and hunger.

How Tariffs Hit Hard: Before And After

Tariffs hurt clothes, jewels, and chemicals most (30-70% less sold). People shipped extra in April (up 18%), but August sales fell 14%. Some exemptions let rivals take business, risking 50,000 small companies.

IT services (half to US, $225 billion) face visa cuts and taxes. Goods could lose $42 billion yearly, services $7 billion in half a year. Total loss: $49 billion, plus big wage hits.

World Trade: Goods vs. Services

Goods sold: $220 billion (up 2.5%). Bought: $368 billion (up 2.5%). Services sold: $199 billion (up 11%), bought $102 billion, extra $97 billion. Total gap: $51 billion.

Weak rupee helps sales but hurts oil buys. August was good, but year-end sales $850-860 billion with higher unemployment.

US As Partner: Challenges And Changes

US buys 17-20% of India’s sales. Goods: $45 billion, services $28 billion, total extra $36 billion. But barriers threaten IT. India is selling more to EU (up 12%) and UAE (up 20%).

Jobs: Growth But Problems

Jobs grew from 470 million in 2014 to 660 million in 2025, thanks to services and gig work (up to 13 million). But most (89%) are informal, no safety. Permanent jobs are just 10-12%.

Unemployment official: 4-6%, but real higher. Tariffs make it worse for youth.

Table (jobs in crores, gig in millions):

Year	Total Jobs	Permanent	Other	Gig	Jobless (%)	Total Change (%)	Permanent Change (%)	Gig Change (%)
2014	47	4.7	42.3	4	5	–	–	–
2015	48	4.8	43.2	4.5	5	+2	+2	+13
… (shortened for simplicity; pattern shows steady growth, peaks in 2020/23)
2025	66	6.3	59.7	13	6.5	+6.5	+1.6	+6

Social Issues: Poverty, Hunger, Gaps

Poverty down, but 810 million need food aid (56% people). Hunger better but still bad (score 27.3, rank 105). Inequality same, top 1% own 58% wealth.

Average income up from $1,560 (2014) to $2,880 (2025), but behind China ($13,000), US ($83,000). Neighbors: Bangladesh close at $2,690.

Table (incomes $; shortened):

Year	India	China	US	…
2014	1560	7670	55000	…
2025	2880	13000	83000	…

Stocks Drop From Tariffs

August fall 8-10%, $500-700 billion gone. Indexes down 0.2-4% this year.

Table:

Index	2024 Up (%)	2025 So Far (%)	Why
Nifty 50	12	-1	Tariffs, rivals
Sensex	12	-0.2	Weekly drops

Key Areas And Pressures

Drugs up 10%, IT up 12% but risky. Oil buys $100 billion. Shift to Asia for sales.

India-China Trade: Big Gap

Deficit $101 billion (2024). This half-year: Sell $8 billion, buy $61 billion, gap $53 billion. Growing over years.

2025-26 Future: GDP Predicted To Be 2.5-4% In 25-26

Growth could drop to 2.5-4% if not fixed. Sales over $850 billion, gap under $100 billion, jobless 6.5%. Keep US ties in green energy. Fix China gap by selling elsewhere.

Plan: Push sales, make real jobs, help gig workers, cut imports. Turn problems into better growth, fix poverty.

India’s services sector remains a cornerstone of its external economic stability, recording a strong net surplus of approximately $97.5 billion for April–September 2025. This estimate draws from Reserve Bank of India (RBI) data through August, with September trends extrapolated based on observed patterns, marking a 14% year-over-year (YoY) rise. Services exports totaled ~$199.2 billion, fueled by robust expansion in information technology (IT), software, business process outsourcing (BPO), and nascent fields like artificial intelligence (AI) and cloud computing. Imports were ~$101.8 billion, growing at a more modest 3.8% YoY, primarily in transport, travel, and tech inputs. This services surplus substantially mitigates the merchandise goods trade deficit, estimated at ~$148 billion for the period (with goods exports ~$220 billion and imports ~$368 billion) , resulting in a current account deficit of just 0.2% of GDP, according to RBI’s Q1 FY25-26 Balance of Payments (BoP) report.

The services performance highlights India’s edge in knowledge-based exports, with cumulative growth through August at 10.6% YoY. Computer and software services hold a 60% share, followed by business services at 25%. Bilateral breakdowns are constrained by data lags from RBI and the World Trade Organization (WTO), but prorated 2024 baselines adjusted for 2025 growth indicate surpluses with most partners. The following analysis uses non-overlapping regional aggregates to prevent double-counting, encompassing ~94% of exports through key destinations like the US, UK, EU, Canada, and Asia.

To contextualise the pivotal US role—accounting for over half of services exports and contributing significantly to India’s overall trade surplus—this report compares US-India dynamics with India-China trade patterns. Unlike the balanced, surplus-generating US ties (driven by services and select goods), India-China relations feature a persistent, widening goods deficit with negligible services offset, underscoring structural vulnerabilities.

India-China Trade: A Contrasting Deficit-Driven Landscape (2014–2024)

India’s trade with China has ballooned over the decade, but it is overwhelmingly goods-dominated, with India running chronic deficits due to heavy reliance on Chinese imports for electronics, machinery, chemicals, and pharmaceuticals. Bilateral goods trade surged from ~$71.7 billion in 2014 to ~$135 billion in 2024, per data from India’s Ministry of Commerce, UN COMTRADE, and the Observatory of Economic Complexity (OEC).

Exports grew modestly from $11.3 billion to ~$17 billion, while imports exploded from $60.4 billion to ~$118 billion, yielding a cumulative deficit exceeding $700 billion over the period.

Services trade, in contrast, remains marginal—estimated at $1–2 billion annually in both directions, with India’s net services surplus to China hovering around $0.2–0.5 billion yearly, per RBI BoP aggregates and WTO services profiles. This pales against the goods imbalance, highlighting China’s role as a low-cost supplier rather than a balanced partner.

Year	Goods Exports to China ($B)	Goods Imports from China ($B)	Goods Trade Balance ($B)	Total Goods Trade ($B)	Est. Services Exports ($B)	Est. Services Imports ($B)	Est. Services Balance ($B)	Combined Balance ($B)
2014	11.3	60.4	-49.1	71.7	1.2	1.0	0.2	-48.9
2015	9.0	60.4	-51.4	69.4	1.1	0.9	0.2	-51.2
2016	8.0	55.4	-47.4	63.4	1.0	0.8	0.2	-47.2
2017	8.3	59.3	-51.0	67.6	1.2	1.0	0.2	-50.8
2018	16.7	70.3	-53.6	87.0	1.4	1.1	0.3	-53.3
2019	16.7	70.8	-54.1	87.5	1.5	1.2	0.3	-53.8
2020	7.2	65.3	-58.1	72.5	1.3	1.0	0.3	-57.8
2021	21.3	97.5	-76.2	118.8	1.6	1.3	0.3	-75.9
2022	17.4	101.7	-84.3	119.1	1.7	1.4	0.3	-84.0
2023	16.7	101.7	-85.0	118.4	1.8	1.5	0.3	-84.7
2024	17.0	118.0	-101.0	135.0	1.9	1.6	0.3	-100.7

Sources: Ministry of Commerce & Industry (India), UN COMTRADE, RBI BoP, WTO Services Trade Hub. Services estimates prorated from aggregate bilateral flows; actual bilateral services data is limited and often bundled in “other Asia” categories. FY data aligned to calendar years for consistency. Deficits reflect India’s perspective (negative balance).

This asymmetry contrasts sharply with US-India trade, where services surpluses (~$53.6 billion estimated for April–September 2025) complement goods surpluses (~$36 billion cumulative), yielding a combined surplus. China’s dominance in goods imports has fueled concerns over dependency, with deficits widening to a record $99.2 billion (data mismatch, it is more) in FY24-25 (April 2024–March 2025), per Reuters analysis of commerce data.

India-China Trade Snapshot: April–September 2025

For the first half of FY25-26, India-China goods trade mirrors historical patterns, with cumulative bilateral goods trade estimated at ~$67.2 billion (exports ~$7.2 billion, imports ~$60 billion), per OEC monthly data and Ministry of Commerce extrapolations through August, with September preliminary. Monthly averages show exports at ~$1.2 billion (e.g., $1.38 billion in June, up 16.4% YoY, led by petroleum products and telecom instruments) and imports at ~$10 billion (e.g., $11.2 billion in June, up 9.4% YoY, dominated by electronics and machinery). The goods deficit stands at ~$52.8 billion. Services trade remains subdued at ~$0.6 billion exports and ~$0.5 billion imports (net +$0.1 billion), focused on business and transport services. Overall combined deficit: ~$52.7 billion—over half the period’s goods deficit, with no meaningful services offset.

Category	Exports ($B)	Imports ($B)	Balance ($B)	Key Drivers
Goods	7.2	60.0	-52.8	Exports: Petroleum ($1.4B), iron ore ($0.7B). Imports: Electronics ($20B), machinery ($15B). YoY import growth 8%, amid supply chain reliance.
Services	0.6	0.5	+0.1	Business/IT services exports; transport imports. Minimal YoY change.
Combined	7.8	60.5	-52.7	Persistent goods drag; services negligible (1% of total).

Sources: OEC (June 2025 data), Ministry of Commerce (April–August cumulatives), RBI preliminary BoP. September extrapolated at 10% below August due to seasonal slowdowns. Estimates ±5% uncertainty.

In comparison, US-India trade for the same period yields a combined surplus of ~$89.6 billion (~$53.6 billion services + $36 billion goods), per article baselines and US Census/BEA data. This underscores the US as a surplus partner, while China exacerbates India’s overall trade gap.

US-India Trade Growth: Pre-Tariff Surge Amid Tariff And Non-Tariff Pressures

US-India bilateral trade expanded significantly in 2024–2025, reaching ~$129 billion in goods (2024 full year, per US Census Bureau) and ~$83.4 billion in services (2024 BEA annuals), with India’s combined surplus climbing to ~$60 billion annually by mid-2025. For April–September 2025, goods trade averaged ~$12.5 billion monthly (India exports ~$8.8 billion, imports ~$3.7 billion; surplus ~$5.1 billion monthly), while services held steady at ~$6.95 billion monthly total (India surplus ~$3.6 billion). This growth—18% YoY in goods exports to the US (April–August, per Ministry of Commerce)—was propelled by anticipation of US tariffs and easing of select non-tariff barriers (NTBs), alongside structural factors like supply chain diversification from China.

Drivers Of Pre-Tariff Expansion (January–August 2025)

(a) Tariff Anticipation and Front-Loading: US President Donald Trump’s April 2, 2025, Executive Order (EO 14257) imposed a baseline 10% tariff on all imports, with “reciprocal” escalations for high-deficit partners like India (initially 25% announced July 31, effective August 7, doubling to 50% on August 27 for non-compliant nations).

Importers rushed shipments pre-deadline, boosting Indian goods exports by 22% in July 2025 ($9.17 billion) from June ($9.15 billion), per US Census. Sectors like textiles, apparel, and gems/jewelry saw 30–40% spikes, as firms stockpiled to avoid post-August duties.

India, not qualifying as an aligned partner due to trade imbalances and Russian oil purchases, faces a 50% tariff on most exports (effective August 27, 2025), affecting ~$60.2 billion in U.S.-bound trade. This could reduce exports by 70% in some sectors and slow GDP growth by 0.5-1%.

The exemptions create a price gap, with aligned partners’ goods entering at near-zero duties versus India’s 50%, leading to market share shifts, supply chain reconfigurations, and investment diversions. India’s U.S. exports could drop $20-30 billion annually, while competitors surge 20-40%.

(b) Non-Tariff Barriers (NTBs) Easing: US complaints over India’s “obnoxious” NTBs—such as quality control orders (QCOs) on electronics and steel, localisation mandates, and data protection rules—eased partially in early 2025. The US-India Terms of Reference (April 2025, USTR) led to India relaxing QCOs on 20% of affected goods (e.g., certain IT hardware), unlocking $5–7 billion in annual exports. However, persistent NTBs like US Buy American policies and cybersecurity reviews slowed some goods inflows.

However, the situation has changed after August 2025. Based on various reports, the estimated loss to India in 2025 from such U.S. restrictions on Indian services is approximately $7 billion in foregone exports and related revenue.

India’s services exports to the US are dominated by IT and BPM, making up over 60% of total services trade. The total value of Indian services exports to the US in 2024 was $41.6 billion, with projections for 2025 showing growth to around $45-50 billion absent restrictions. However, NTBs could reduce this by 10-15%, contributing to the $7 billion loss estimate.

(c) Geopolitical And Supply Chain Shifts: India’s diversification from China (post-2020 border tensions) funneled $10–15 billion in redirected US-bound exports (e.g., pharmaceuticals up 25% YoY). US incentives under the CHIPS Act and Inflation Reduction Act favored Indian suppliers, adding $3 billion in semiconductor-related services. Stats: India’s goods surplus with the US hit $5 billion monthly in May 2025 (exports $9.43 billion), per Economic Times, versus $4.5 billion average in 2024.

(d) Quantitative Impact: Pre-tariff (April–July 2025), goods exports totaled $36.6 billion (up 18% YoY), services $27.8 billion (up 14%). Front-loading added ~$4–5 billion to goods volumes, per GTRI estimates, but risked post-tariff corrections.

India shipped ~80% of projected August–September goods pre-tariff deadlines, preserving surpluses temporarily. Services, immune to physical shipment rushes, maintained steady growth. But post August /September 2025 things would become nasty for Indian services too due to U.S. NTBs.

Post-August 2025 US Tariffs: Impacts, Exemptions, And Barriers On India

Effective August 27, 2025, the US escalated tariffs to 50% on most Indian goods (via EO amendments), targeting the $45.8 billion 2024 US goods deficit. This “reciprocal” measure punishes India’s Russian oil purchases (25% penalty layer) and aims to force market openings. Aligned partners (e.g., those signing framework pacts like the UK) gain exemptions—zero duties on 45+ categories (metals, pharma, chemicals)—but India, lacking a deal, faces full exposure. NTBs compound this: US reviews intensified on Indian steel (anti-dumping duties up 20%) and digital services (data localization probes).

Impacts On Goods Trade

Tariffs hit ~70% of Indian exports ($60+ billion annually affected), projecting a 43% drop in US-bound goods ($38 billion in 2025 full year, down from $87.4 billion in 2024). August 2025 saw exports dip to $6.86 billion (from $9.17 billion in July), per Reuters/Ministry data, with textiles/apparel down 25%. Exemptions shield pharma/electronics (~30% of exports, $26 billion), but non-exempt sectors like auto parts face 50% duties, shaving 0.3% off India’s GDP (Moody’s). NTBs add friction: US FDA delays on Indian generics cost $1–2 billion quarterly.

Sector/Category	Pre-Tariff Exports (Apr–Jul 2025, $B)	Post-Tariff Projection (Aug–Sep 2025, $B)	Impact (% Change)	Key Factors
Pharma/Electronics (Exempt)	12.5	6.5	-5%	Zero duties; aligned exemptions partial (India negotiating). NTBs minimal.
Textiles/Apparel	8.0	3.2	-60%	50% tariff + NTB quality checks; front-loading exhausted.
Gems/Jewelry/Auto	10.1	4.0	-60%	Full 50% hit; US localization preferences. Deficit for US shrinks $2B/month.
Total Goods	36.6	15.7	-57%	Overall surplus falls to $1.5B/month; $10B annual loss projected.

Impacts On Services Trade

Services face no direct tariffs but indirect NTBs: US visa caps (H-1B reduced 10% in 2025) and data rules threaten IT/BPO (80% of $103.6 billion exports). Growth slowed to 8% YoY in August (BEA: US imports from India $18.5 billion Q3 prelim.). Exemptions via “digital trade pacts” could shield, but delays risk $7 billion annual hit. Net surplus dips to $2.8 billion/month post-August.

Category	Pre-Tariff Exports (Apr–Jul 2025, $B)	Post-Tariff Projection (Aug–Sep 2025, $B)	Impact (% Change)	Key Factors
IT/Software/BPO	21.0	10.5	-10%	Visa/NTB pressures; no tariff but regulatory scrutiny up.
Business/R&D	6.8	3.5	-15%	US cybersecurity reviews; partial exemptions negotiated.
Total Services	27.8	14.0	-10%	Surplus to $2.8B/month; $8B annual erosion if NTBs persist.

Combined Goods And Services Impact (Post-August 2025)

Aggregated, bilateral trade volumes contract 35–40%, with India’s surplus halving to ~$4.3 billion/month (August prelim: $4.7 billion). Full-year 2025 projection: combined trade $190 billion (down 15% from 2024), surplus $45 billion (vs. $60 billion). Geopolitical risks (e.g., oil-linked penalties) could add $3 billion in costs; negotiations for aligned status might recover 20% via exemptions.

Month/Period	Goods Surplus ($B)	Services Surplus ($B)	Combined Surplus ($B)	Total Bilateral ($B)	YoY Change (%)
Aug 2025 (Actual)	1.0	2.8	3.8	14.0	-25%
Sep 2025 (Est.)	1.5	2.8	4.3	15.5	-20%
Post-Aug Total (Q3–Q4 Proj.)	12.0	22.4	34.4	120.0	-30%

Sources: US Census/BEA (July–August data), USTR EOs, GTRI/Moody’s projections, Reuters. Impacts include 50% tariffs on 70% goods; NTBs add 10–15% effective barrier. Exemptions cover ~25% if India aligns by Q4.

Bilateral And Regional Services Trade Balances

India’s services trade favors surpluses with advanced economies via IT/BPO strengths, while Asia shows mixed results due to energy/logistics imports. Prorated estimates cover ~94% of exports.

Partner/Region	Estimated Exports ($B)	Estimated Imports ($B)	Estimated Net Surplus ($B)	Share of Total Exports (%)	Key Notes
US	103.6	50.0	53.6	52	IT/software (80%); 15% YoY pre-tariff boost, but post-Aug NTBs slow growth. Exemptions eyed for digital flows.
UK	13.9	4.0	9.9	7	Finance/BPO; UK-India FTA (July 2025) aids 12% growth. Low NTB exposure.
EU (aggregate)	35.9	15.0	20.9	18	Germany/France/Netherlands lead; 12% YoY via FTA talks. Business services key.
Canada	4.0	1.0	3.0	2	IT/professionals; 8% growth. Minimal barriers.
Asia (aggregate)	29.9	20.0	9.9	15	China/Japan/Singapore/UAE; 10% YoY via RCEP. Imports high in logistics; contrasts US surplus.
Subtotal	187.3	90.0	97.3	94	Aligns with aggregate; US tariffs indirectly pressure via rupee volatility.

Emerging Markets: Trade With The Rest of the World

~6% of services exports (~$11.9 billion) target Africa, Latin America, Oceania, non-EU Europe, and others, yielding ~$8.0 billion surplus (exports $11.9B; imports $3.9B). High margins (65–70%) from low imports signal Global South diversification.

Sub-Region/Group	Share of Total Exports (%)	Estimated Exports ($B)	Estimated Imports ($B)	Estimated Surplus ($B)	Key Insights
Africa	1.5	3.0	0.8	2.2	Business/education; 12% growth via AfCFTA.
Latin America	1.0	2.0	0.5	1.5	IT to Brazil/Mexico; 15% YoY.
Oceania	1.5	3.0	0.8	2.2	Professionals; 12% from Australia ECTA.
Non-EU Europe	1.0	2.0	0.7	1.3	Finance to Switzerland; Russia offsets minor.
Other	1.0	2.0	1.1	0.9	Tourism/IT; low-volume.
Total Remaining	6	11.9	3.9	8.0	+10–15% YoY; offsets US tariff risks.

Spotlight: US-India Trade Dynamics Amid Tariff Turbulence

The US-India axis exemplifies services strength, with ~$6.95 billion monthly services trade (14% of India’s global services). Goods show US deficit (~$6B monthly average pre-tariff). Post-August tariffs disrupt, but pre-tariff front-loading sustained April–August momentum.

US-India Services Trade (April–September 2025)

Month	Estimated Bilateral Total ($B)	% of India’s Global Services Trade
April 2025	6.95	14%
May 2025	6.95	14%
June 2025	6.95	14%
July 2025	6.95	14%
August 2025	6.95 (prelim.)	14%
September 2025	~6.5 (est., NTB impact)	~13%

US-India Goods Trade (April–September 2025)

Month	US Exports to India ($M)	US Imports from India ($M)	Bilateral Total ($B)	India’s Global Goods Total ($B)	% of India’s Global	India’s Goods Surplus with US ($M)
April 2025	3,959.6	10,029.2	13.99	96.5	14.5%	6,069.6
May 2025	3,819.1	9,433.9	13.25	95.2	13.9%	5,614.8
June 2025	3,805.8	9,153.4	12.96	94.8	13.7%	5,347.6
July 2025	3,406.0	9,170.6	12.58	95.1	13.2%	5,764.6
August 2025	3,406.0 (est.)	6,860.0	10.27	96.7	10.6%	3,454.0
September 2025	~3,200 (est.)	~6,500 (est.)	~9.7	~95.0	~10%	~3,300

Combined US-India Goods And Services Trade

Month	Bilateral Combined Total ($B)	India’s Global Combined Total ($B)	% of India’s Global
April 2025	20.94	146.0	14.3%
May 2025	20.20	145.1	13.9%
June 2025	19.91	144.7	13.8%
July 2025	19.53	145.1	13.5%
August 2025	17.22	146.5	11.8%
September 2025	~16.2 (est.)	~145.0	~11%

BEA confirms July US services imports at $265 billion (up from $252.4 billion June), with India contributing via IT.

Broader Implications And Outlook

The $97.5 billion services surplus (14% YoY) fortifies forex reserves (~$680 billion, August 2025) and rupee stability. US ties (53% of surplus) drive core growth, but post-August tariffs/NTBs threaten $15–20 billion in annual losses, per GTRI. China contrasts as a deficit sink, emphasising diversification needs. Catalysts: EU/UK FTAs, RCEP; risks: Asian imports, US barriers. India eyes aligned exemptions via talks.

Official data pending RBI Q2 BoP (late October 2025), WTO 2025. Sources: RBI BoP Q1 (Sep 1, 2025), PIB August, WTO 2024, US BEA/Census, Ministry of Commerce, USTR EOs, Reuters/GTRI. Estimates ±5–10% from prorations/extrapolations.